1. SAN CARLOS, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming virtual investor conferences:

    HC Wainwright 23rd Annual Global Investment Conference
    September 13-15, 2021
    Presentation available beginning September 13

    Baird Global Healthcare Conference
    September 14-15, 2021
    Fireside chat time: 3:00 p.m. EDT, Wednesday, September 15

    An audio webcast of the HC Wainwright presentation will be available on-demand beginning at 7:00 a.m. Eastern Time on September 13, 2021, and…

    SAN CARLOS, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming virtual investor conferences:

    HC Wainwright 23rd Annual Global Investment Conference

    September 13-15, 2021

    Presentation available beginning September 13

    Baird Global Healthcare Conference

    September 14-15, 2021

    Fireside chat time: 3:00 p.m. EDT, Wednesday, September 15

    An audio webcast of the HC Wainwright presentation will be available on-demand beginning at 7:00 a.m. Eastern Time on September 13, 2021, and can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. The presentation will be available on the Company's website for 90 days.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and typically are identified by use of terms such as "continued," "anticipate," "potential," "expect," "believe," "planned," and similar words, although some forward-looking statements are expressed differently. These statements include those related to our strategy and future plans, including statements regarding the development of ATRC-101 and our preclinical, clinical and regulatory plans and the timing thereof. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our filings with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251, ext. 251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.



    Primary Logo

    View Full Article Hide Full Article
  2. SAN CARLOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2021, and provided an overview of recent developments.

    "We recently announced initial summary data from the dose escalation portion of the Phase 1b trial evaluating ATRC-101 in multiple solid tumors," said John Orwin, Chief Executive Officer. "ATRC-101 was well-tolerated in the study, and we believe that the initial signs of activity, which were associated with expression of ATRC-101's target, provide…

    SAN CARLOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2021, and provided an overview of recent developments.

    "We recently announced initial summary data from the dose escalation portion of the Phase 1b trial evaluating ATRC-101 in multiple solid tumors," said John Orwin, Chief Executive Officer. "ATRC-101 was well-tolerated in the study, and we believe that the initial signs of activity, which were associated with expression of ATRC-101's target, provide strong rationale for further evaluation. Additionally, we believe the data provide validation of the ability of our discovery platform to identify druggable tumor targets shared across broad groups of patients. We look forward to providing an update on our early-stage pipeline in the coming months as well as reporting additional monotherapy in 1H22, pembrolizumab combination data in mid-2022, and chemotherapy combination data in late 2022."

    Recent Developments and Highlights

    • Atreca announced initial summary data from the dose escalation portion of the Phase 1b trial of ATRC-101 in multiple solid tumors. ATRC-101 was well-tolerated with no dose-limiting toxicities observed. Eight of the 20 participants (40%) evaluable prior to the data cut-off in this analysis experienced stable disease (SD) as their best RECIST response, including four with tumor size reduction. The disease control observed in the study was associated with ATRC-101 target expression, and preliminary biomarker analysis was consistent with the proposed mechanism of action for ATRC-101.The peak concentration of ATRC-101 was dose proportional and minimal accumulation was observed following multiple doses.

    • Phase 1b monotherapy dose expansion of ATRC-101 is ongoing at 30 mg/kg. A combination study evaluating ATRC-101 with pembrolizumab is active and another combination study with pegylated liposomal doxorubicin is expected to begin enrolling patients in 4Q21. Atreca expects to report additional monotherapy data in 1H22, pembrolizumab combination data in mid-2022 and chemotherapy combination data in late 2022.

    • Supported by data from the dose escalation portion of the trial, Atreca is developing a diagnostic to enable prospective patient selection based on target expression.

    Second Quarter 2021 Financial Results

    • As of June 30, 2021, cash and cash equivalents and short-term investments totaled $182.3 million.
    • Research and development expenses for the three months ended June 30, 2021 were $19.0 million, including non-cash share-based compensation expense of $1.9 million.

    • General and administrative expenses for the three months ended June 30, 2021 were $8.0 million, including non-cash share-based compensation expense of $2.0 million.

    • Atreca reported a net loss of $26.7 million, or basic and diluted net loss per share attributable to common stockholders of $0.72, for the three months ended June 30, 2021.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and typically are identified by use of terms such as "continued," "anticipate," "potential," "expect," "believe," "planned," and similar words, although some forward-looking statements are expressed differently. These statements include those related to our strategy and future plans, including statements regarding the development of ATRC-101 and our preclinical, clinical and regulatory plans and the timing thereof, the availability and timing of data from the monotherapy dose escalation portions of the Phase 1b trial and from combinations evaluating ATRC-101 with pembrolizumab and with chemotherapy, and our development of a diagnostic to enable prospective patient selection based on target expression. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our filings with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.



    Atreca, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands, except share and per share data)

         
      June 30, December 31,
       2021   2020 
      (unaudited)  
    ASSETS    
         
    Current Assets
    Cash and cash equivalents $93,603  $60,789 
    Investments  88,708   179,296 
    Prepaid expenses and other current assets  10,579   9,037 
    Total current assets  192,890   249,122 
    Property and equipment, net  45,099   19,831 
    Deposits and other  2,852   3,111 
    Total assets $240,841  $272,064 
         
    LIABILITIES AND STOCKHOLDERS' EQUITY
         
    Current Liabilities
    Accounts payable $3,596  $5,216 
    Accrued expenses  8,633   10,302 
    Other current liabilities  2,078   1,900 
    Total current liabilities  14,307   17,418 
    Capital lease obligations, net of current portion  -   4 
    Deferred rent  27,931   12,585 
    Total liabilities  42,238   30,007 
         
         
    Stockholders' equity
    Common stock  4   4 
    Additional paid-in capital  501,474   492,436 
    Accumulated other comprehensive income  16   58 
    Accumulated deficit  (302,891)  (250,441)
    Total stockholders' equity  198,603   242,057 
    Total liabilities and stockholders' equity $240,841  $272,064 
         



    Atreca, Inc.

    Condensed Consolidated Statements of Operations

    (in thousands, except share and per share data)

    (unaudited)

    ($ amounts in 000's, except per share amounts)       
              
       Three Months Ended Six Months Ended
       June 30, June 30,
        2021   2020   2021   2020 
              
    Expenses        
     Research and development $19,036  $14,180  $37,424  $28,390 
     General and administrative  8,031   6,458   15,852   13,581 
     Total expenses  27,067   20,638   53,276   41,971 
    Interest and other income (expense)        
     Other income  349   403   693   634 
     Interest income  56   255   147   940 
     Interest expense  (1)  (1)  (2)  (2)
     Loss on disposal of property and equipment  (11)  -   (11)  - 
    Loss before Income tax expense  (26,674)  (19,981)  (52,449)  (40,399)
    Income tax expense  (1)  -   (1)  - 
    Net loss $(26,675) $(19,981) $(52,450) $(40,399)
    Net loss per share, basic and diluted $(0.72) $(0.71) $(1.42) $(1.44)
    Weighted-average shares used in computing        
    net loss per share, basic and diluted  36,893,827   28,144,714   36,867,592   28,082,930 
              

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.



    Primary Logo

    View Full Article Hide Full Article
  3. SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming virtual investor conferences:

    Wedbush PacGrow Healthcare Conference
    Tuesday, August 10, 2021
    Panel discussion time: 1:10 p.m. EDT
    Panel title: Heavenly (anti)Bodies

    Canaccord Genuity 41st Annual Growth Conference
    Thursday, August 12, 2021
    Fireside chat time: 3:00 p.m. EDT

    A live audio webcast of the Canaccord presentation can be accessed through the Events & Presentations section of the Company's website at…

    SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming virtual investor conferences:

    Wedbush PacGrow Healthcare Conference

    Tuesday, August 10, 2021

    Panel discussion time: 1:10 p.m. EDT

    Panel title: Heavenly (anti)Bodies

    Canaccord Genuity 41st Annual Growth Conference

    Thursday, August 12, 2021

    Fireside chat time: 3:00 p.m. EDT

    A live audio webcast of the Canaccord presentation can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. An archived replay will be available on the Company's website for 90 days following the live presentation.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and typically are identified by use of terms such as "continued," "anticipate," "potential," "expect," "believe," "planned," and similar words, although some forward-looking statements are expressed differently. These statements include those related to our strategy and future plans, including statements regarding the development of ATRC-101 and our preclinical, clinical and regulatory plans and the timing thereof. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our filings with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251, ext. 251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.



    Primary Logo

    View Full Article Hide Full Article
  4. Completed dose escalation portion of Phase 1b trial; ATRC-101 was well-tolerated with no dose-limiting toxicities observed

    Disease control associated with ATRC-101 target expression; preliminary biomarker data support the proposed mechanism of action (MOA) as elucidated in preclinical studies

    Phase 1b monotherapy dose expansion ongoing; developing diagnostic to select patients based on target expression

    Conference call and webinar scheduled for today at 8:00 a.m. ET

    SAN CARLOS, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response…

    Completed dose escalation portion of Phase 1b trial; ATRC-101 was well-tolerated with no dose-limiting toxicities observed

    Disease control associated with ATRC-101 target expression; preliminary biomarker data support the proposed mechanism of action (MOA) as elucidated in preclinical studies

    Phase 1b monotherapy dose expansion ongoing; developing diagnostic to select patients based on target expression

    Conference call and webinar scheduled for today at 8:00 a.m. ET

    SAN CARLOS, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced initial data from the dose escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types that displayed greater than 50% target expression in preclinical studies.

    "We are pleased to present initial summary data from our first-in-human study of ATRC-101," said Jonathan Benjamin, M.D., Ph.D., Sr. Vice President, Clinical Research. "We are very encouraged by the results observed thus far in a relatively small set of heavily pre-treated participants. ATRC-101, which targets a novel tumor antigen and acts via a novel MOA in oncology, was well-tolerated at all doses evaluated in the study with no dose-limiting toxicities observed. Furthermore, disease control is associated with ATRC-101 target expression, and the preliminary biomarker analysis is consistent with the proposed MOA for ATRC-101. We anticipate reporting additional data from monotherapy dose expansion cohorts in the Phase 1b trial and from combination cohorts evaluating ATRC-101 with pembrolizumab in 2022, and initiating additional combination cohorts evaluating ATRC-101 with chemotherapy later this year."

    "ATRC-101 represents a new approach in cancer research," said Dr. John Powderly, M.D., Founder and President of the Carolina BioOncology Institute. "While these data are from a limited number of treatment-refractory patients, I was pleased to see that ATRC-101 was well-tolerated and appears to have an informative biomarker. I look forward to continue investigating the potential of ATRC-101 in cancer patients."

    ATRC-101 Phase 1b Study Design

    The Phase 1b trial is a first-in-human, open-label study of ATRC-101 in patients with select solid tumor cancers, utilizing a 3+3 design for the dose escalation portion. Enrollment is limited to patients with tumor types reactive to ATRC-101 in more than 50% of historical patient samples evaluated preclinically, which includes non-small cell lung, breast, ovarian, and colorectal cancer, as well as acral melanoma. The objectives of the study are to characterize safety, determine a maximum tolerated or recommended dose for expansion, measure initial clinical activity, and characterize potential biomarkers of activity in tumors, plasma, and peripheral blood mononuclear cells (PBMC).

    Initial Study Results

    A total of 26 participants had been dosed in the trial as of the data cut-off date of July 16th, including 24 participants treated at five once-every-21-day (q21d) dose levels, 0.3 mg/kg (n = 3), 1 mg/kg (n = 3), 3 mg/kg (n = 9), 10 mg/kg (n = 6), and 30 mg/kg (n = 3), and two participants treated at one once-every-14-day (q14d) dose level, 1 mg/kg (n = 2). Tumor types enrolled in the q21d cohorts were colorectal (n = 13), ovarian (n = 5), breast (n = 3), non-small cell lung (n = 2) and acral melanoma (n = 1). Participants enrolled in the study had received a median of five prior lines of treatment. Of the 26 participants dosed, 24 participants treated with any dose of ATRC-101 were evaluable for safety, 19 for PK, 20 for clinical response, and 18 participants for target expression.

    Pharmacokinetics (PK)

    The peak concentration of ATRC-101 was dose proportional and minimal accumulation was observed following multiple doses. ATRC-101's half-life was 10.5 days and was relatively consistent across all dose levels.

    Safety

    ATRC-101 was generally well-tolerated, with no dose-limiting toxicities at doses ≤30 mg/kg. Thirty-three percent of participants (n = 8) had at least one grade ≥ 3 adverse event (AE). Respiratory failure (n = 2) and sepsis (n = 2) were the only grade ≥ 3 AEs observed in more than one participant, and the one grade 4 treatment-emergent AE observed was a case of acute respiratory failure. The most common treatment-related AEs were fatigue (n = 5, 21%), nausea (n = 4, 17%), and tumor pain (n = 4, 17%).

    Disease Efficacy Observations

    Eight of the 20 participants (40%) evaluable prior to the data cut-off in this analysis experienced stable disease (SD) as their best RECIST response, including four with tumor reduction observed. The remaining 12 participants had progressive disease as their best RECIST response. Disease control observed in the study was associated with target expression, as 3 of 6 (50%) of participants with evaluable response assessments and baseline tumor H-scores ≥50 achieved SD, compared with 1 of 9 (11%) evaluable participants with an H-score <50.

    Biomarkers

    Preliminary biomarker evaluation supports the proposed MOA of ATRC-101 initially proposed from preclinical studies. Expansion of peripheral blood CD8+ T cells was observed at day 8 following dosing with ATRC-101 among participants with evaluable baseline tumor biopsies and tumor H-scores ≥50. Preliminary observations of serum cytokines appeared consistent with the proposed MOA of innate immune system activation leading to an adaptive immune response against tumor.

    Next Steps

    Phase 1b monotherapy dose expansion is ongoing at 30 mg/kg, a combination study evaluating ATRC-101 with pembrolizumab is active and another combination study with pegylated liposomal doxorubicin is expected to begin enrolling patients in 4Q21. Atreca expects to report additional monotherapy data by mid-2022, pembrolizumab combination data in mid-2022 and chemotherapy combination data in late 2022. Supported by data from the dose escalation portion of the trial, Atreca is developing a diagnostic to select patients based on target expression.

    "We are very pleased with the results of the Phase 1b study presented today and look forward to the continued clinical development of ATRC-101 as both a monotherapy and in combination studies," said John Orwin, Chief Executive Officer of Atreca. "ATRC-101 is the first anti-cancer agent discovered via Atreca's platform to be tested in humans, and we believe that the activity observed in the trial provides a strong rationale for further investigation. Furthermore, we believe that these data provide validation for the ability of our discovery platform to identify novel, druggable tumor targets shared across groups of patients. We would like to thank all of the patients who enrolled, their families, and their caregivers for participating in this study."

    ATRC-101 Conference Call and Webcast Information

    Atreca will host a conference call/webcast today at 8:00 a.m. ET. The live webcast, including slides, can be accessed through the Events & Presentations section of the Company's website at https://ir.atreca.com/news-and-events/event-calendar. To access the conference call, please dial (800) 373-6606 (United States) or (409) 937-8918 (international) and reference the conference ID 2386207. An archived replay of the webcast will be available on the Company's website for 90 days following the live event.

    About ATRC-101

    ATRC-101 is a monoclonal antibody derived from an antibody identified using Atreca's discovery platform. ATRC-101 is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology. This mechanism involves systemic delivery of an antibody that, in preclinical models, engages the innate immune system to cause remodeling of the tumor microenvironment and drive T cell-mediated destruction of tumor cells. Atreca has identified the target of ATRC-101 as a tumor-specific ribonucleoprotein (RNP) complex. ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical syngeneic tumor models, including one model in which PD-1 checkpoint inhibitors typically display limited activity. Further, ATRC-101 has been shown to react in vitro with a majority of human ovarian, non-small cell lung, colorectal, breast cancers and acral melanoma samples from multiple patients. Atreca initiated a Phase 1b first-in-human study of ATRC-101 in participants with select solid tumor cancers in early 2020. Clinical trials to evaluate ATRC-101 in combination with a PD-1 inhibitor and in combination with chemotherapy are planned for 2021, as well as in monotherapy dose expansion cohorts in the ongoing Phase 1b trial.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling participants. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and typically are identified by use of terms such as "continued," "anticipate," "potential," "expect," "believe," "planned," and similar words, although some forward-looking statements are expressed differently. These statements include those related to our strategy and future plans, including statements regarding the development of ATRC-101 and our preclinical, clinical and regulatory plans and the timing thereof, the availability and timing of data from monotherapy dose expansion cohorts in the Phase 1b trial and from combination cohorts evaluating ATRC-101 with pembrolizumab and with pegylated liposomal doxorubicin, initiating additional combination cohorts evaluating ATRC-101 with chemotherapy, trends consistent with the proposed MOA of innate immune system activation, and our development of a diagnostic to select patients based on target expression. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our filings with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.

     



    Primary Logo

    View Full Article Hide Full Article
  5. SAN CARLOS, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced it will host a webinar to present initial data from the dose escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types on Thursday, July 29, 2021, at 8:00 a.m. ET.

    Conference Call and Webcast Information

    The live webcast, including slides, can be accessed through the Events & Presentations section of the Company's website at https://ir.atreca.com/news-and-events/event-calendar. To access the conference call, please…

    SAN CARLOS, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced it will host a webinar to present initial data from the dose escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types on Thursday, July 29, 2021, at 8:00 a.m. ET.

    Conference Call and Webcast Information

    The live webcast, including slides, can be accessed through the Events & Presentations section of the Company's website at https://ir.atreca.com/news-and-events/event-calendar. To access the conference call, please dial (800) 373-6606 (United States) or (409) 937-8918 (international) and reference the conference ID 2386207. An archived replay of the webcast will be available on the Company's website following the live event.

    About ATRC-101

    ATRC-101 is a monoclonal antibody derived from an antibody identified using Atreca's discovery platform. ATRC-101 is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology. This mechanism involves systemic delivery of an antibody that, in preclinical models, engages the innate immune system to cause remodeling of the tumor microenvironment and drive T cell-mediated destruction of tumor cells. Atreca has identified the target of ATRC-101 as a tumor-specific ribonucleoprotein (RNP) complex. ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical syngeneic tumor models, including one model in which PD-1 checkpoint inhibitors typically display limited activity. Further, ATRC-101 has been shown to react in vitro with a majority of human ovarian, non-small cell lung, colorectal, breast cancers and acral melanoma samples from multiple patients. Atreca initiated a Phase 1b first-in-human study of ATRC-101 in patients with select solid tumor cancers in early 2020. Clinical trials to evaluate ATRC-101 in combination with a PD-1 inhibitor and in combination with chemotherapy are planned for 2021, as well as in monotherapy dose expansion cohorts in the ongoing Phase 1b trial.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and typically are identified by use of terms such as "continued," "anticipate," "potential," "expect," "believe," "planned," and similar words, although some forward-looking statements are expressed differently. These statements include those related to our strategy and future plans, including statements regarding the development of ATRC-101 and our preclinical, clinical and regulatory plans and the timing thereof, the availability and timing of data from monotherapy dose expansion cohorts in the Phase 1b trial and from combination cohorts evaluating ATRC-101 with a PD-1 inhibitor and with chemotherapy. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our filings with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.

     



    Primary Logo

    View Full Article Hide Full Article
  6. SAN CARLOS Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Dr. Stacey Ma, Executive Vice President and Head of Technical Operations at Sana Biotechnology, and Stephen R. Brady, Chief Executive Officer of Tempest Therapeutics, to its Board of Directors.

    "We are pleased to be expanding our Board of Directors with the addition of two experienced and accomplished biopharmaceutical executives" said John Orwin, Chief Executive Officer. "Together, Stacey and Steve bring over 40 years of industry experience…

    SAN CARLOS Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Dr. Stacey Ma, Executive Vice President and Head of Technical Operations at Sana Biotechnology, and Stephen R. Brady, Chief Executive Officer of Tempest Therapeutics, to its Board of Directors.

    "We are pleased to be expanding our Board of Directors with the addition of two experienced and accomplished biopharmaceutical executives" said John Orwin, Chief Executive Officer. "Together, Stacey and Steve bring over 40 years of industry experience across a variety of corporate functions, including research, technical operations, manufacturing, corporate development and finance. Their expertise will be invaluable to Atreca as we continue to advance ATRC-101 and build our preclinical pipeline."

    Dr. Stacey Ma

    Dr. Ma is currently the Executive Vice President and Head of Technical Operations at Sana Biotechnology, a publicly listed biotechnology company, where she has served since March 2019. From 1996 to 2019, she served various roles at Genentech/Roche, a biotechnology company, including as their Global Head of Innovation, Manufacturing Science and Technology from March 2018 to March 2019, and as Vice President, Global Head of Investigational Medicinal Products (IMP) Quality from May 2015 to February 2018. From July 1996 to May 2015, she held various other roles related to analytical development, pharmaceutical development, quality, technical product management and supply chain.

    Stephen R. Brady

    Mr. Brady is currently the Chief Executive Officer of Tempest Therapeutics, a publicly listed biotechnology company. Previously, he served as the President and Chief Operating Officer at Tempest from September 2019 to June 2021. Prior to joining Tempest, he served in various leadership roles at Immune Design Corp., including as Executive Vice President, Strategy & Finance from May 2015 until its sale to Merck in 2019, and as Chief Business Officer from September 2013 to May 2015. Prior to Immune Design, Mr. Brady served in various leadership roles at 3-V Biosciences, Inc. (now known as Sagimet Biosciences Inc.), including as Chief Business Officer from February 2011 to August 2013, and as Vice President, Corporate Development, Strategy and Operations from February 2010 to February 2011. From April 2007 to March 2010, Mr. Brady held various roles at Proteolix, Inc., most recently serving as Vice President of Corporate Development.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and typically are identified by use of terms such as "continued," "anticipate," "potential," "expect," "believe," "planned," and similar words, although some forward-looking statements are expressed differently.  The statements include those related to our strategy and future plans, including statements regarding the development of ATRC-101 and our preclinical, clinical and regulatory plans and the timing thereof, and the availability and timing of data from the Phase 1b trial of ATRC-101.  Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, and regulatory submissions, and the implementation of our strategic plans for our business, technologies, and current and potential future product candidates. More information on these risks and potential factors that could affect our business and financial results is included in our filings with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.



    Primary Logo

    View Full Article Hide Full Article
  7. SAN CARLOS, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming virtual investor conferences:

    Cowen 2nd Annual Virtual Oncology Innovation Summit
    Friday, May 21, 2021
    Fireside chat time: 10:40 a.m. EDT

    Jefferies Virtual Healthcare Conference
    Wednesday, June 2, 2021
    Fireside chat time: 3:30 p.m. EDT

    A live audio webcast of each presentation can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. Archived replays will be available on the Company's…

    SAN CARLOS, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming virtual investor conferences:

    Cowen 2nd Annual Virtual Oncology Innovation Summit

    Friday, May 21, 2021

    Fireside chat time: 10:40 a.m. EDT

    Jefferies Virtual Healthcare Conference

    Wednesday, June 2, 2021

    Fireside chat time: 3:30 p.m. EDT

    A live audio webcast of each presentation can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. Archived replays will be available on the Company's website for 90 days following the live presentations.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    Certain statements in this press release regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans and the timing thereof, constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, and regulatory submissions, the activity of ATRC-101 or potential future candidates once administered in human subjects, and the implementation of our strategic plans for our business, technologies, and current or potential future product candidates. More information on these risks and potential factors that could affect our business and financial results is included in our filings with the U.S. Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including in our most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and subsequent filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251, ext. 251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.



    Primary Logo

    View Full Article Hide Full Article
  8. SAN CARLOS Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the first quarter ended March 31, 2021, and provided an overview of recent developments.

    "The first few months of 2021 have been a productive period at Atreca, and we look forward to reporting initial summary data from our Phase 1b trial of ATRC-101 in July of this year," said John Orwin, Chief Executive Officer. "We are making good progress enrolling the monotherapy cohorts, and are moving quickly to commence the combination cohorts…

    SAN CARLOS Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the first quarter ended March 31, 2021, and provided an overview of recent developments.

    "The first few months of 2021 have been a productive period at Atreca, and we look forward to reporting initial summary data from our Phase 1b trial of ATRC-101 in July of this year," said John Orwin, Chief Executive Officer. "We are making good progress enrolling the monotherapy cohorts, and are moving quickly to commence the combination cohorts evaluating ATRC-101 with both checkpoint inhibitors targeting the PD-1/PD-L1 axis and with chemotherapy. We also continue to advance our pre-clinical pipeline and are excited to announce our next program, targeting EphA2."

    Recent Developments and Highlights

    ATRC-101 Clinical Update        

    To date, 20 patients have been enrolled and treated in the first-in-human trial evaluating ATRC-101 in multiple solid tumor cancers. Atreca has completed enrollment in the fourth cohort (10 mg/kg) of the dose escalation portion of the trial, and all patients treated at that dose have now completed the 21 day dose-limiting toxicity (DLT) assessment period. No DLTs have been observed in the trial. Atreca and its investigators decided, out of an abundance of caution, to enroll three additional patients in the fourth dose cohort (10 mg/kg), after the first two patients enrolled experienced rapid deterioration associated with disease progression, assessed as unrelated to ATRC-101, relatively soon after completion of the DLT assesment period. Atreca anticipates commencing enrollment in the fifth and final cohort (30 mg/kg) shortly, pending review by the Dose Review Committee, and expects to announce initial summary data from the study in July 2021.

    Enrollment includes additional patients treated at 3 mg/kg through backfill of the third dose escalation cohort and the initiation of a monotherapy dose expansion cohort, as previously disclosed. Atreca expects to enroll additional cohorts evaluating ATRC-101 in combination with a PD-1 inhibitor and in combination with a chemotherapeutic agent in 2Q 2021 and 2H 2021, respectively.

    Pipeline Update        

    Atreca has designated a second program, with APN-122597, an antibody derived from the active immune response of a cancer patient, as the program lead. APN-122597 binds to a membrane proximal extracellular epitope of EphA2, a receptor tyrosine kinase (RTK) validated as a known tumor target that is overexpressed in multiple cancers, but with no approved therapies targeting it. A human normal tissue cross-reactivity study showed no reactivity of toxicological significance, and APN-122597 is active in vitro in multiple formats. Atreca expects to provide additional information on APN-122597 and other pipeline assets, including timelines for development, at an R&D Day in 4Q 2021.

    "APN-122597 is another example of the power of our discovery approach," said Dr. Tito Serafini, Atreca founder and Chief Strategy Officer. "While EphA2 is validated as a known and potentially high value target, there are only a limited number of development-stage programs currently targeting EphA2, and no therapies on the market. We believe our antibody is differentiated by its apparent lack of both EphA2 activation and interference with ligand-induced activation, its unique patterns of reactivity with tumor tissue and cells, and its structural features. Furthermore, lead optimization has already yielded improved molecules with an anticipated low level of sequence-based CMC risk."

    IP Update        

    In April 2021, the United States Patent and Trademark Office issued a Notice of Allowance for U.S. patent application serial no. 13/261,763 (exclusively licensed to Atreca), covering fundamental aspects of Atreca's Immune Repertoire Capture® technology (IRC®), which forms a core part of the company's discovery platform. This patent, once issued, further bolsters our global patent coverage for compositions of matter that are a key output of Atreca's IRC® technology.

    First Quarter 2021 Financial Results

    • As of March 31, 2021, cash and cash equivalents and short-term investments totaled $211.7 million.



    • Research and development expenses for the three months ended March 31, 2021 were $18.4 million, including non-cash share-based compensation expense of $2.2 million.



    • General and administrative expenses for the three months ended March 31, 2021 were $7.8 million, including non-cash share-based compensation expense of $2.2 million.



    • Atreca reported a net loss of $25.8 million, or basic and diluted net loss per share attributable to common stockholders of $0.70, for the three months ended March 31, 2021.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and typically are identified by use of terms such as "continued," "anticipate," "potential," "expect," "believe," "planned," and similar words, although some forward-looking statements are expressed differently. The statements include those related to our strategy and future plans, including statements regarding the development of ATRC-101 and our preclinical, clinical and regulatory plans and the timing thereof, the availability and timing of data from the Phase 1b trial of ATRC-101, our plans and timing to commence combination cohorts evaluating ATRC-101 with checkpoint inhibitors and chemotherapy, and our pre-clinical plans for our next program targeting EphA2 and the differentiation of our antibody in this program. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, and regulatory submissions, and the implementation of our strategic plans for our business, technologies, and current and potential future product candidates. More information on these risks and potential factors that could affect our business and financial results is included in our filings with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law. 

    Atreca, Inc. 
    Condensed Consolidated Balance Sheets 
    (in thousands, except share and per share data) 
          
      March 31, December 31, 
          2021   2020     
          
    ASSETS     
          
    Current Assets
    Cash and cash equivalents $89,712  $60,789  
    Investments  121,958   179,296  
    Prepaid expenses and other current assets  13,109   9,037  
    Total current assets  224,779   249,122  
    Property and equipment, net  33,948   19,831  
    Deposits and other  3,076   3,111  
    Total assets $261,803  $272,064  
          
    LIABILITIES AND STOCKHOLDERS' EQUITY
          
    Current Liabilities
    Accounts payable $7,525  $5,216  
    Accrued expenses  9,133   10,302  
    Other current liabilities  2,097   1,900  
    Total current liabilities  18,755   17,418  
    Capital lease obligations, net of current portion  -   4  
    Deferred rent  21,649   12,585  
    Total liabilities  40,404   30,007  
          
          
    Stockholders' equity
    Common stock  4   4  
    Additional paid-in capital  497,561   492,436  
    Accumulated other comprehensive income  50   58  
    Accumulated deficit  (276,216)  (250,441) 
    Total stockholders' equity  221,399   242,057  
    Total liabilities and stockholders' equity $261,803  $272,064  
          

     

    Atreca, Inc.

    Condensed Consolidated Statements of Operations

    (in thousands, except share and per share data)

    (unaudited)



    ($ amounts in 000's, except per share amounts)    
           
       Three Months Ended 
       March 31, 
        2021   2020  
       (unaudited) 
    Expenses     
     Research and development $18,388  $14,210  
     General and administrative  7,821   7,123  
     Total expenses  26,209   21,333  
    Interest and other income (expense)     
     Other income  344   231  
     Interest income  91   685  
     Interest expense  (1)  (1) 
    Loss before Income tax expense  (25,775)  (20,418) 
    Income tax expense  -   -  
    Net loss $(25,775) $(20,418) 
    Net loss per share, basic and diluted $(0.70) $(0.73) 
    Weighted-average shares used in computing     
    net loss per share, basic and diluted  36,841,065   28,020,408  
           

     

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.



    Primary Logo

    View Full Article Hide Full Article
  9. REDWOOD CITY, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

    20th Annual Needham Virtual Healthcare Conference
    Tuesday, April 13, 2021
    Presentation time: 1:30 p.m. EDT

    Canaccord Genuity Horizons in Oncology Virtual Conference
    Thursday, April 15, 2021
    Panel time: 4:00 p.m. EDT

    A live audio webcast of the Needham presentation can be accessed through the Events & Presentations section of the company's website at ir.atreca.com. An archived replay will…

    REDWOOD CITY, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

    20th Annual Needham Virtual Healthcare Conference

    Tuesday, April 13, 2021

    Presentation time: 1:30 p.m. EDT

    Canaccord Genuity Horizons in Oncology Virtual Conference

    Thursday, April 15, 2021

    Panel time: 4:00 p.m. EDT

    A live audio webcast of the Needham presentation can be accessed through the Events & Presentations section of the company's website at ir.atreca.com. An archived replay will be available on the company's website for 90 days following the live presentation.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    Certain statements in this press release regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans and the timing thereof, constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, and regulatory submissions, the activity of ATRC-101 or potential future candidates once administered in human subjects, and the implementation of our strategic plans for our business, technologies, and current or potential future product candidates. More information on these risks and potential factors that could affect our business and financial results is included in our filings with the U.S. Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including in our most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and subsequent filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com 

    Source: Atreca, Inc.



    Primary Logo

    View Full Article Hide Full Article
  10. SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that a trial-in-progress poster will be presented at the virtual AACR Annual Meeting, which is being held over two one-week periods: April 10 – 15 and May 17 – 21 2021. The poster will describe the design of the company's ongoing Phase 1b first-in-human clinical trial evaluating ATRC-101 as monotherapy and in combination with pembrolizumab in patients with solid tumor cancers.

    Details of the presentation are as follows:

    Title: First-in-human…

    SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that a trial-in-progress poster will be presented at the virtual AACR Annual Meeting, which is being held over two one-week periods: April 10 – 15 and May 17 – 21 2021. The poster will describe the design of the company's ongoing Phase 1b first-in-human clinical trial evaluating ATRC-101 as monotherapy and in combination with pembrolizumab in patients with solid tumor cancers.

    Details of the presentation are as follows:

    Title: First-in-human phase 1b study of ATRC-101, a patient-derived antibody with a tumor-specific target, as monotherapy or in combination with pembrolizumab, in patients with solid tumors

    Session Title: Phase I Clinical Trials in Progress

    Abstract Number: CT203

    Full text of abstract will be released on the AACR website at 12:01 a.m. EDT on Friday, April 9 and the poster will be made available on the company's website once the virtual program begins on Saturday, April 10.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    Certain statements in this press release regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans and the timing thereof, constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, and regulatory submissions, the activity of ATRC-101 or potential future candidates once administered in human subjects, and the implementation of our strategic plans for our business, technologies, and current or potential future product candidates. More information on these risks and potential factors that could affect our business and financial results is included in our filings with the U.S. Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including in our most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and subsequent filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com 

    Source: Atreca, Inc.



    Primary Logo

    View Full Article Hide Full Article
  11. SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of recent developments.

    "2020 was a successful year for Atreca marked by several key milestones, including the initiation of our first-in-human study of ATRC-101 and the signing of multiple strategic collaborations to both enhance our discovery platform and build our development pipeline," said John Orwin, Chief Executive Officer. "Preclinical…

    SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of recent developments.

    "2020 was a successful year for Atreca marked by several key milestones, including the initiation of our first-in-human study of ATRC-101 and the signing of multiple strategic collaborations to both enhance our discovery platform and build our development pipeline," said John Orwin, Chief Executive Officer. "Preclinical data that we presented on ATRC-101 throughout the year highlighted its novel target and mechanism of action, as well as its potential as a combination therapy both with checkpoint inhibitors targeting the PD-1/PD-L1 axis and with chemotherapy. This year we look forward to reporting initial summary data from our Phase 1b trial, initiating combination studies with a checkpoint inhibitor and chemotherapy, and providing an update on our early-stage pipeline."

    Recent Developments and Highlights

    • To date, 10 clinical trial sites have been initiated in the Phase 1b trial evaluating ATRC-101 in multiple solid tumor cancers. Three patients have been enrolled in the fourth dose cohort (10mg/kg) of the dose escalation portion of the trial. Patient enrollment in the fifth and final dose cohort (30mg/kg) is planned to begin following the protocol-specified dose-limiting toxicity assessment period. Atreca expects to announce initial summary data from the study in 2Q 2021.

    • As allowed by the study protocol, up to three additional patients are being backfilled into the previously cleared third dose cohort (3mg/kg) due to continued interest in the study and in order to collect supplemental data. The dose expansion portion of the study is also being opened with an additional 3mg/kg cohort expected to enroll up to 12 patients. Further cohorts to evaluate ATRC-101 in combination with a PD-1 inhibitor and in combination with a chemotherapeutic agent are planned to begin in 2Q 2021 and 2H 2021, respectively.

    Fourth Quarter and Full Year 2020 Financial Results

    • As of December 31, 2020, cash and cash equivalents and short-term investments totaled $240.1 million.



    • Research and development expenses for the year ended December 31, 2020 were $62.0 million, including non-cash share-based compensation expense of $5.9 million. Research and development expenses for the three months ended December 31, 2020 were $16.8 million, including non-cash share-based compensation expense of $1.4 million.



    • General and administrative expenses for the year ended December 31, 2020 were $26.8 million, including non-cash share-based compensation expense of $6.6 million. General and administrative expenses for the three months ended December 31, 2020 were $6.6 million, including non-cash share-based compensation expense of $1.7 million.



    • Atreca reported a net loss of $86.3 million, or basic and diluted net loss per share attributable to common stockholders of $2.70, for the year ended December 31, 2020. The Company reported a net loss of $23.0 million, or basic and diluted net loss per share attributable to common stockholders of $0.63, for the three months ended December 31, 2020.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    Certain statements in this press release regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans and the timing thereof, and the progress of our discovery platform and development efforts with our existing and potential future collaboration and research arrangements, constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "continued," "anticipate," "potential," "expect," "believe," "planned," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, and regulatory submissions, the activity of ATRC-101 or potential future candidates once administered in human subjects, and the implementation of our strategic plans for our business, technologies, and current or potential future product candidates. More information on these risks and potential factors that could affect our business and financial results is included in our filings with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.



    Atreca, Inc. 
    Condensed Consolidated Balance Sheets 
    (in thousands, except share and per share data) 
          
      December 31,

     December 31, 
      2020 2019 
          
    ASSETS     
          
    Current Assets
    Cash and cash equivalents $60,789  $157,954  
    Investments  179,296   14,663  
    Prepaid expenses and other current assets  9,037   3,502  
    Total current assets  249,122   176,119  
    Property and equipment, net  19,831   5,771  
    Long-term investments  -   10,799  
    Deposits and other  3,111   3,026  
    Total assets $272,064  $195,715  
          
    LIABILITIES AND STOCKHOLDERS' EQUITY
          
    Current Liabilities
    Accounts payable $5,216  $2,133  
    Accrued expenses  10,302   5,395  
    Other current liabilities  1,900   419  
    Total current liabilities  17,418   7,947  
    Capital lease obligations, net of current portion  4   53  
    Deferred rent  12,585   763  
    Total liabilities  30,007   8,763  
          
          
    Stockholders' equity
    Common stock  4   3  
    Additional paid-in capital  492,436   351,039  
    Accumulated other comprehensive income  58   16  
    Accumulated deficit  (250,441)  (164,106) 
    Total stockholders' equity  242,057   186,952  
    Total liabilities and stockholders' equity $272,064  $195,715  
          

     

    Atreca, Inc.
    Condensed Consolidated Statements of Operations
    (in thousands, except share and per share data)
              
       Three Months Ended Year Ended
       December 31, December 31,
        2020  2019  2020  2019
            
       (unaudited)    
    Expenses        
     Research and development $16,847  $14,279  $62,045  $54,726 
     General and administrative  6,639   6,926   26,834   17,845 
     Total expenses  23,486   21,205   88,879   72,571 
    Interest and other income (expense)        
     Other income  366   329   1,353   2,134 
     Interest income  136   885   1,218   3,213 
     Interest expense  (1)  (1)  (4)  (6)
     Preferred stock warrant liability revaluation   —    —    —   (123)
     Foreign exchange loss   —   (7)   —   (8)
     Loss on disposal of property and equipment  (22)  (115)  (22)  (122)
    Loss before Income tax expense  (23,007)  (20,114)  (86,334)  (67,483)
    Income tax expense  -   1   (1)  (1)
    Net loss $(23,007) $(20,113) $(86,335) $(67,484)
    Net loss per share, basic and diluted $(0.63) $(0.72) $(2.70) $(4.26)
    Weighted-average shares used in computing        
    net loss per share, basic and diluted  36,726,441   27,959,975   31,924,473   15,834,175 
              

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.

     

     



    Primary Logo

    View Full Article Hide Full Article
  12. SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

    Cowen 41st Annual Health Care Conference
    Date: Monday, March 1, 2021
    Panel discussion time: 1:20 p.m. EST
    Title: "Novel Oncology Targets"

    H.C. Wainwright Global Life Sciences Conference
    Date: Tuesday, March 9, 2021
    Presentation time: 7:00 a.m. EST

    33rd Annual Roth Conference
    Date: Tuesday, March 16, 2021
    Fireside chat time: 4:00 p.m. EDT

    A live audio webcast of the H.C…

    SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

    Cowen 41st Annual Health Care Conference

    Date: Monday, March 1, 2021

    Panel discussion time: 1:20 p.m. EST

    Title: "Novel Oncology Targets"

    H.C. Wainwright Global Life Sciences Conference

    Date: Tuesday, March 9, 2021

    Presentation time: 7:00 a.m. EST

    33rd Annual Roth Conference

    Date: Tuesday, March 16, 2021

    Fireside chat time: 4:00 p.m. EDT

    A live audio webcast of the H.C. Wainwright and Roth presentations can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. An archived replay of both presentations will be available on the Company's website for 90 days following the live event.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.



    Primary Logo

    View Full Article Hide Full Article
  13. SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent developments.

    "We continued to make progress enrolling patients and activating trial sites in our Phase 1b trial of ATRC-101 during the third quarter and anticipate reporting initial summary data in the first half of 2021," said John Orwin, Chief Executive Officer. "We recently presented preclinical data at SITC 2020 further highlighting the…

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent developments.

    "We continued to make progress enrolling patients and activating trial sites in our Phase 1b trial of ATRC-101 during the third quarter and anticipate reporting initial summary data in the first half of 2021," said John Orwin, Chief Executive Officer. "We recently presented preclinical data at SITC 2020 further highlighting the potential for ATRC-101 as a combination therapy with checkpoint inhibitors targeting the PD-1/PD-L1 axis. We expect to initiate combination studies with a checkpoint inhibitor as well as with chemotherapy, and to commence monotherapy expansion cohorts, in 2021."

    Recent Developments and Highlights

    • Screening in the Phase 1b first-in-human study evaluating ATRC-101 in patients with select solid tumor cancers is ongoing, and patients are currently being enrolled in the third dose cohort. To date, seven clinical trial sites have been activated, including two additional sites in the third quarter of 2020, and Atreca expects to announce initial summary data from the study in the first half of 2021. In addition to monotherapy expansion cohorts, clinical trials of ATRC-101 in combination with a PD-1 inhibitor and in combination with a chemotherapeutic are planned for 2021.



    • Atreca presented two posters describing preclinical evaluations of ATRC-101 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020). The presentations provide insight into the cooperation between checkpoint inhibitors targeting the PD-1/PD-L1 axis and ATRC-101 as well as the potent single-agent activity of ATRC-101 in syngeneic mouse tumor models. Both posters are currently available on Atreca's website.

    Third Quarter 2020 Financial Results

    • As of September 30, 2020, cash, cash equivalents and investments totaled $259.5 million.



    • Research and development expenses for the three months ended September 30, 2020 were $16.8 million, including non-cash share-based compensation expense of $1.6 million.



    • General and administrative expenses for the three months ended September 30, 2020 were $6.6 million, including non-cash share-based compensation expense of $1.9 million.



    • Atreca reported a net loss of $22.9 million, or basic and diluted net loss per share attributable to common stockholders of $0.66, for the three months ended September 30, 2020.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "continued," "anticipate," "potential," "expect," "believe," "planned," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

     
     
    Atreca, Inc.
    Condensed Consolidated Balance Sheets
    (in thousands, except share and per share data)
         
      September 30,December 31, 
       2020   2019 
         
    ASSETS    
         
    Current Assets
    Cash and cash equivalents $133,072  $157,954 
    Investments  126,192   14,663 
    Prepaid expenses and other current assets  4,898   3,502 
    Total current assets  264,162   176,119 
    Property and equipment, net  7,783   5,771 
    Long-term investments  205   10,799 
    Deposits and other  3,043   3,026 
    Total assets $275,193  $195,715 
         
    LIABILITIES AND STOCKHOLDERS' EQUITY
         
    Current Liabilities
    Accounts payable $2,524  $2,133 
    Accrued expenses  5,309   5,395 
    Other current liabilities  1,442   419 
    Total current liabilities  9,275   7,947 
    Capital lease obligations, net of current portion  17   53 
    Deferred rent  4,621   763 
    Total liabilities  13,913   8,763 
         
         
    Stockholders' equity
    Common stock  4   3 
    Additional paid-in capital  488,593   351,039 
    Accumulated other comprehensive income  117   16 
    Accumulated deficit  (227,434)  (164,106)
    Total stockholders' equity  261,280   186,952 
    Total liabilities and stockholders' equity $275,193  $195,715 
         





     
    Atreca, Inc.
    Condensed Consolidated Statements of Operations
    (in thousands, except share and per share data)
           (unaudited)
              
       Three Months Ended Nine Months Ended
       September 30, September 30,
        2020   2019   2020   2019 
    Expenses        
     Research and development $16,808  $12,812  $45,198  $40,447 
     General and administrative  6,614   4,864   20,195   10,919 
     Total expenses  23,422   17,676   65,393   51,366 
    Interest and other income (expense)        
     Other income  353   619   987   1,805 
     Interest income  142   1,189   1,082   2,328 
     Interest expense  (1)  (1)  (3)  (5)
     Preferred stock warrant liability revaluation           (123)
     Foreign exchange loss     (1)     (1)
     Loss on disposal of property and equipment           (7)
    Loss before Income tax expense  (22,928)  (15,870)  (63,327)  (47,369)
    Income tax expense  (1)  (1)  (1)  (2)
    Net loss $(22,929) $(15,871) $(63,328) $(47,371)
    Net loss per share, basic and diluted $(0.66) $(0.57) $(2.09) $(4.03)
    Weighted-average shares used in computing        
    net loss per share, basic and diluted  34,723,888   27,949,682   30,313,047   11,747,825 
              



    Contacts


    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251, ext. 251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com 

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  14. SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

    Cowen 2020 Next IO Summit
    Friday, November 13, 2020
    Fireside Chat time: 2:45 p.m. EST

    Stifel 2020 Virtual Healthcare Conference
    Wednesday, November 18, 2020
    Fireside Chat time: 4:40 p.m. EST

    Evercore ISI 3rd Annual HealthCONx
    Wednesday, December 2, 2020
    Panel Discussion time: 10:30 a.m. EST
    Title: "Finders Keepers: Identifying New Cancer Targets"

    Live audio webcasts of the…

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:

    Cowen 2020 Next IO Summit

    Friday, November 13, 2020

    Fireside Chat time: 2:45 p.m. EST

    Stifel 2020 Virtual Healthcare Conference

    Wednesday, November 18, 2020

    Fireside Chat time: 4:40 p.m. EST

    Evercore ISI 3rd Annual HealthCONx

    Wednesday, December 2, 2020

    Panel Discussion time: 10:30 a.m. EST

    Title: "Finders Keepers: Identifying New Cancer Targets"

    Live audio webcasts of the Cowen and Stifel presentations can be accessed through the Events & Presentations section of the company's website at ir.atreca.com. An archived replay of each webcast will be available on the company's website for 90 days following the live presentations.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  15. SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two upcoming poster presentations describing preclinical evaluations of ATRC-101 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020. ATRC-101 is a novel, first-in-class therapeutic candidate derived from a human antibody discovered by Atreca, which targets a tumor-associated ribonucleoprotein (RNP) complex and is currently in Phase 1b clinical development.

    Details are…

    SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two upcoming poster presentations describing preclinical evaluations of ATRC-101 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020. ATRC-101 is a novel, first-in-class therapeutic candidate derived from a human antibody discovered by Atreca, which targets a tumor-associated ribonucleoprotein (RNP) complex and is currently in Phase 1b clinical development.

    Details are as follows:

    Title: Cooperation Between Checkpoint Inhibitors Targeting the PD-1/PD-L1 Axis and ATRC-101, a Novel Clinical-Stage Candidate for the Treatment of Solid Tissue Malignancies

    Authors: Amy Manning-Bog, Ph.D., et al.

    Poster/Abstract Number: 469

    Title: ATRC-101 Drives Potent Single-Agent Activity in Mouse Syngeneic Tumor Models via a Novel Cellular Mechanism of Action

    Authors: Alexander Scholz, Ph.D., et al.

    Poster/Abstract Number: 689

    Abstracts and posters can be accessed on the SITC website once the conference begins on Monday, November 9th at 8:00 a.m. EDT. The posters will also be made available on the Atreca website.

    About ATRC-101

    ATRC-101 is a monoclonal antibody derived from an antibody identified using Atreca's discovery platform. ATRC-101 is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology. This mechanism involves systemic delivery of an antibody that, in preclinical models, engages the innate immune system to cause remodeling of the tumor microenvironment and drive T cell-mediated destruction of tumor cells. Atreca has identified the target of ATRC-101 as a tumor-specific ribonucleoprotein (RNP) complex. ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical syngeneic tumor models, including one model in which PD-1 checkpoint inhibitors typically display limited activity. Further, ATRC-101 has been shown to react in vitro with a majority of human ovarian, non-small cell lung, colorectal, breast cancers and acral melanoma samples from multiple patients. Atreca initiated a Phase 1b first-in-human study of ATRC-101 in patients with select solid tumor cancers in early 2020. Clinical trials to evaluate ATRC-101 in combination with a PD-1 inhibitor and in combination with chemotherapy are planned for 2021, as well as in monotherapy dose expansion cohorts in the ongoing Phase 1b trial.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "believe," "planned," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 949-903-4750

    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  16. SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences: 

    H.C. Wainwright & Co. 22nd Annual Global Investment Conference 2020
    Wednesday, September 16, 2020
    Presentation time: 3:30 p.m. EDT

    Morgan Stanley Virtual Global Healthcare Conference 2020
    Thursday, September 17, 2020
    Presentation time: 3:30 p.m. EDT

    A live audio webcast of each presentation can be accessed through the Events & Presentations section of the Company's website at…

    SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences: 

    H.C. Wainwright & Co. 22nd Annual Global Investment Conference 2020

    Wednesday, September 16, 2020

    Presentation time: 3:30 p.m. EDT

    Morgan Stanley Virtual Global Healthcare Conference 2020

    Thursday, September 17, 2020

    Presentation time: 3:30 p.m. EDT

    A live audio webcast of each presentation can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. An archived replay of each webcast will be available on the Company's website for 90 days following the live presentations.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  17. SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2020, and provided an overview of recent developments.

    "The second quarter was eventful for Atreca as we continue to execute on our various development objectives," said John Orwin, Chief Executive Officer. "We recently presented preclinical data for ATRC-101 demonstrating that its novel target is induced by chemotherapeutics and further validating its novel mechanism of action. Our Phase…

    SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2020, and provided an overview of recent developments.

    "The second quarter was eventful for Atreca as we continue to execute on our various development objectives," said John Orwin, Chief Executive Officer. "We recently presented preclinical data for ATRC-101 demonstrating that its novel target is induced by chemotherapeutics and further validating its novel mechanism of action. Our Phase 1b first-in-human study evaluating ATRC-101 continues to enroll patients and now has five trial sites active. In addition, our recently announced strategic collaboration with Xencor to develop bispecific T cell-engaging antibodies underscores the value of novel targets in oncology and the ability of our technology platform to attract weaponization partners. We believe these milestones, coupled with our strengthened financial position from the completion an equity financing in July, position us well for continued progress in the second half of 2020."

    Recent Developments and Highlights

    • A Phase 1b first-in-human study evaluating ATRC-101 in patients with select solid tumor cancers is ongoing. Screening continues in the study and patients are currently being enrolled in the second dose cohort. To date, five clinical trial sites have been activated. Atreca expects to announce initial safety data from the study in late 2020 or early 2021. In addition to monotherapy expansion cohorts, clinical trials of ATRC-101 in combination with a PD-1 inhibitor and in combination with a chemotherapeutic are planned for 2021.

       
    • Atreca hosted a webinar in June to present new preclinical data regarding the novel target and mechanism of action of ATRC-101, demonstrating both innate and adaptive immune system activation and target induction via chemotherapy.

       
    • Atreca entered into a strategic collaboration and license agreement with Xencor, Inc. to research, develop and commercialize T cell-engaging bispecific antibodies as potential therapeutics in oncology. Under a three-year discovery program, Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells. Up to two joint programs will be mutually selected for further development and commercialization, with each partner sharing 50 percent of costs and profits. Atreca and Xencor may also pursue up to two programs independently, with a mid-to high-single digit percent royalty payable on net sales.

       
    • Atreca strengthened its financial position with the completion of a public equity offering in July 2020, resulting in net proceeds of approximately $117.5 million.

       
    • Atreca appointed Ms. Kristine M. Ball to the Company's board of directors. Ms. Ball brings more than 25 years of life sciences industry experience focused primarily on finance, corporate development and strategic planning.

       
    • Atreca continues to collaborate with BeiGene, and IGM Biosciences on a potential novel antibody treatment for COVID-19.

    Second Quarter 2020 Financial Results

    • As of June 30, 2020, cash, cash equivalents and investments totaled $148.8 million. In addition, Atreca completed a public equity offering in July 2020 resulting in net proceeds of approximately $117.5 million, and after deducting the underwriting discounts and commissions and estimated offering expenses.

       
    • Research and development expenses for the three months ended June 30, 2020 were $14.2 million, including non-cash share-based compensation expense of $1.8 million.

       
    • General and administrative expenses for the three months ended June 30, 2020 were $6.5 million, including non-cash share-based compensation expense of $1.6 million.

       
    • Atreca reported a net loss of $20.0 million, or basic and diluted net loss per share attributable to common stockholders of $0.71, for the three months ended June 30, 2020.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will", "believe," "potential," "continue," "expects," "planned," "may," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Atreca, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands, except share and per share data)

          
     June 30,  December 31,  
     2020  2019 
          
    ASSETS     
          
    Current Assets
    Cash and cash equivalents$  100,430  $  157,954 
    Investments  43,088    14,663 
    Prepaid expenses and other current assets  5,112    3,502 
    Total current assets  148,630    176,119 
    Property and equipment, net  7,666    5,771 
    Long-term investments  5,311    10,799 
    Deposits and other  2,934    3,026 
    Total assets$  164,541  $  195,715 
          
    LIABILITIES AND STOCKHOLDERS' EQUITY
          
    Current Liabilities
    Accounts payable $  1,060  $  2,133 
    Accrued expenses  4,434    5,395 
    Other current liabilities  1,859    419 
    Total current liabilities  7,353    7,947 
    Capital lease obligations, net of current portion  29    53 
    Deferred rent  2,887    763 
    Other non-current liabilities  157    -  
    Total liabilities  10,426    8,763 
          
          
    Stockholders' equity
    Common stock  3    3 
    Additional paid-in capital  358,401    351,039 
    Accumulated other comprehensive income  216    16 
    Accumulated deficit  (204,505)   (164,106)
    Total stockholders' equity   154,115    186,952 
    Total liabilities and stockholders' equity $  164,541  $  195,715 
          



    Atreca, Inc.

    Condensed Consolidated Statements of Operations

    (in thousands, except share and per share data)

    (unaudited)

    ($ amounts in 000's, except per share amounts)           
                 
      Three Months Ended

      Six Months Ended

     
      June 30,

      June 30,

     
      2020  2019  2020  2019 
    Expenses           
     Research and development$  14,180  $  15,922  $  28,390  $  27,635 
     General and administrative  6,458    3,537    13,581    6,055 
     Total expenses  20,638    19,459    41,971    33,690 
    Interest and other income (expense)           
     Other income  403    1,021    634    1,186 
     Interest income  255    594    940    1,139 
     Interest expense  (1)   (2)   (2)   (4)
     Preferred stock warrant liability revaluation  —     (73)   —     (123)
     Loss on disposal of property and equipment  —     (2)   —     (7)
    Loss before Income tax expense  (19,981)   (17,921)   (40,399)   (31,499)
    Income tax expense  -     -     -     (1) 
    Net loss$  (19,981) $  (17,921) $  (40,399) $  (31,500)
    Net loss per share, basic and diluted$  (0.71) $  (3.67) $  (1.44) $  (8.97)
    Weighted-average shares used in computing            
    net loss per share, basic and diluted  28,144,714    4,888,987    28,082,930    3,512,606 
                 



    Contacts



    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Primary Logo

    View Full Article Hide Full Article
  18. SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in two upcoming investor conferences:

    2020 Wedbush PacGrow Healthcare Virtual Conference
    Wednesday, August 12, 2020
    Presentation time: 2:20 p.m. EDT

    Canaccord Genuity 40th Annual Growth Conference
    Thursday, August 13, 2020
    Presentation time: 4:00 p.m. EDT

    Live webcasts of each event can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. Archived replays of the webcasts will…

    SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in two upcoming investor conferences:

    2020 Wedbush PacGrow Healthcare Virtual Conference

    Wednesday, August 12, 2020

    Presentation time: 2:20 p.m. EDT

    Canaccord Genuity 40th Annual Growth Conference

    Thursday, August 13, 2020

    Presentation time: 4:00 p.m. EDT

    Live webcasts of each event can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. Archived replays of the webcasts will be available on the Company's website for 90 days following the live presentations.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com

    Investors:

    Alex Gray, 650-779-9251, ext. 251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  19. SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (NASDAQ:BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced the pricing of its previously announced underwritten public offering of 7,031,250 shares of its Class A Common Stock and 781,250 shares of its Class B Common Stock (the "Shares"), each at a price to the public of $16.00 per share. Gross proceeds to Atreca from the offering are expected to be $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.  In addition, Atreca has granted the underwriters a 30-day option to purchase…

    SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (NASDAQ:BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced the pricing of its previously announced underwritten public offering of 7,031,250 shares of its Class A Common Stock and 781,250 shares of its Class B Common Stock (the "Shares"), each at a price to the public of $16.00 per share. Gross proceeds to Atreca from the offering are expected to be $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.  In addition, Atreca has granted the underwriters a 30-day option to purchase up to 1,171,875 additional shares of its Class A Common Stock at the public offering price, less underwriting discounts and commissions.  The offering is expected to close on or about July 20, 2020, subject to the satisfaction of customary closing conditions. All of the shares are being offered by Atreca.

    Cowen and Company, LLC, Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. Canaccord Genuity LLC is acting as lead manager for the offering. Roth Capital Partners, LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC are acting as co-managers for the offering.

    A shelf registration statement relating to the offered Shares was filed with the Securities and Exchange Commission (SEC) on July 2, 2020, and was declared effective on July 10, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and a final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC's website, located at www.sec.gov. The offering is being made only by means of a prospectus supplement and accompanying prospectus.  Copies of the final prospectus supplement and the accompanying prospectus related to the offering may be obtained, when available, from Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attention: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, by email at ecm.prospectus@evercore.com, or by telephone at (888) 474-0200; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at 415-364-2720 or by email at syndprospectus@stifel.com.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    Cautionary Note on Forward-Looking Statements

    This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Atreca's expectations regarding the completion and timing of the public offering. In some cases, you can identify these statements by forward-looking words such as "expect," "will," "may," or the negative or plural of these words or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements are based on Atreca's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the public offering. There can be no assurance that Atreca will be able to complete the public offering on the anticipated terms, or at all. Additional information concerning these and other risks can be found in Atreca's periodic filings with the SEC, including under the heading "Risk Factors" contained therein, as well as the risks identified in the registration statement and the preliminary prospectus supplement relating to the offering. Any forward-looking statements that Atreca makes in this press release speak only as of the date of this press release. Except as required by law, Atreca assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

    Atreca Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Primary Logo

    View Full Article Hide Full Article
  20. REDWOOD CITY, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (NASDAQ:BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced that it intends to offer shares of its Class A Common Stock (the "Shares") in an underwritten public offering. In connection with the offering, Atreca expects to grant the underwriters a 30-day option to purchase additional shares of its Class A Common Stock.  All of the Shares will be offered by Atreca.

    Cowen and Company, LLC, Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. The offering is subject…

    REDWOOD CITY, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (NASDAQ:BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced that it intends to offer shares of its Class A Common Stock (the "Shares") in an underwritten public offering. In connection with the offering, Atreca expects to grant the underwriters a 30-day option to purchase additional shares of its Class A Common Stock.  All of the Shares will be offered by Atreca.

    Cowen and Company, LLC, Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.

    A shelf registration statement relating to the offered Shares was filed with the Securities and Exchange Commission (SEC) on July 2, 2020, and was declared effective on July 10, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website, located at www.sec.gov. Prospective investors should read the preliminary prospectus supplement, when available, and the accompanying prospectus and other documents we have filed with the SEC for more complete information about us and the offering. Copies of the prospectus supplement and the accompanying prospectus related to the offering may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, by email at ecm.prospectus@evercore.com, or by telephone at (888) 474-0200; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at 415-364-2720 or by email at syndprospectus@stifel.com.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    Cautionary Note on Forward-Looking Statements

    This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Atreca's expectations regarding the completion, timing and size of the proposed public offering. In some cases, you can identify these statements by forward-looking words such as "expect," "may," "will,"  or the negative or plural of these words or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements are based on Atreca's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. There can be no assurance that Atreca will be able to complete the proposed public offering on the anticipated terms, or at all. Additional information concerning these and other risks can be found in Atreca's periodic filings with the SEC, including under the heading "Risk Factors" contained therein, as well as the risks identified in the registration statement and the preliminary prospectus supplement relating to the offering. Any forward-looking statements that Atreca makes in this press release speak only as of the date of this press release. Except as required by law, Atreca assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

    Atreca Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Primary Logo

    View Full Article Hide Full Article
  21. Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the companies have entered into a collaboration and license agreement to research, develop and commercialize T cell engaging bispecific antibodies as potential therapeutics in oncology.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200708005295/en/

    Bispecific antibodies…

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the companies have entered into a collaboration and license agreement to research, develop and commercialize T cell engaging bispecific antibodies as potential therapeutics in oncology.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200708005295/en/

    Bispecific antibodies that direct T cells to tumor cells, by simultaneously binding CD3 on T cells and a target on tumor cells, have the potential to drive tumor cell killing. This collaboration will leverage Xencor's XmAb® engineering platform to design and manufacture CD3 bispecific antibodies and Atreca's ability to generate novel antibody-target pairs through its discovery platform, including its Immune Repertoire Capture® (IRC™) technology.

    Under the terms of the agreement, the companies will engage in a three-year discovery program. Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells. Up to two joint programs will be mutually selected for further development and commercialization, with each partner sharing 50 percent of costs and profits. Each company will lead development, regulatory and commercialization activities for one of the joint programs. In addition, the agreement allows for each partner to pursue up to two programs independently, with a mid- to high-single digit percent royalty payable on net sales. Atreca and Xencor began working together in 2019 under a material transfer agreement to accelerate this new collaboration agreement.

    "We are proud to be partnering with Xencor, a leader in the engineering and development of antibody therapeutics," said John A. Orwin, chief executive officer of Atreca. "We believe this collaboration leverages two approaches with the potential to be highly complementary and underscores the value of novel antibody-target pairs in the development of cancer therapeutics. We are encouraged by the work already completed under our initial agreement and look forward to a productive partnership, as well as the prospect of adding T cell engaging bispecific product candidates to our clinical pipeline."

    "Xencor is building a broad portfolio of drug candidates based on our XmAb technologies, which enable us to create therapeutic antibodies and other proteins with enhanced properties and new mechanisms of action," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. "Atreca's unique discovery platform complements our protein engineering capabilities and bispecific platform by providing novel, tumor-selective antibodies and targets to engage with cytotoxic T cell killing. This collaboration offers both Xencor and Atreca with several opportunities to advance novel first-in-class CD3 bispecific antibodies for the potential treatment of patients with cancer."

    About XmAb® Bispecific Fc Technology and CD3 Bispecific Antibodies

    XmAb® bispecific Fc domains enable the rapid design and simplified development of bispecific antibodies, and other protein structures, that can bind two or more different targets simultaneously using an engineered heterodimer Fc domain. CD3 bispecific antibodies contain an anti-tumor associated antigen binding domain and a second binding domain targeted to CD3, an activating receptor on T cells, with the goal to recruit or activate T cells against the antigen target. Xencor has developed a mixed valency format, the XmAb 2+1 bispecific antibody, with two domains that bind a tumor target, which preferentially may bind and kill tumor cells with high target expression while potentially sparing low-expression normal tissues.

    About Xencor, Inc.

    Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 17 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Xencor Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of applicable securities laws, including, but not limited to, the quotations from Xencor's president and chief executive officer and any expectations relating to future product candidates and Xencor's research and development programs. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor's public securities filings. For a discussion of these and other factors, please refer to Xencor's annual report on Form 10-K for the year ended December 31, 2019 as well as Xencor's subsequent filings with the Securities and Exchange Commission. All forward-looking statements are based on Xencor's current information and belief as well as assumptions made by Xencor. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

    Atreca Forward-Looking Statements

    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the potential to add T-cell engaging bispecific product candidates to our clinical pipeline, the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will", "believe," "potential," "prospect," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    XmAb® is a registered trademark of Xencor, Inc.

    Immune Repertoire Capture® is a registered trademark of Atreca, Inc.

    View Full Article Hide Full Article
  22. SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, and Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that the companies have entered into a collaboration and license agreement to research, develop and commercialize T cell-engaging bispecific antibodies as potential therapeutics in oncology.

    Bispecific antibodies that direct T cells to tumor cells, by…

    SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, and Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that the companies have entered into a collaboration and license agreement to research, develop and commercialize T cell-engaging bispecific antibodies as potential therapeutics in oncology.

    Bispecific antibodies that direct T cells to tumor cells, by simultaneously binding CD3 on T cells and a target on tumor cells, have the potential to drive tumor cell killing. This collaboration will leverage Xencor's XmAb® engineering platform to design and manufacture CD3 bispecific antibodies and Atreca's ability to generate novel antibody-target pairs through its discovery platform, including its Immune Repertoire Capture® (IRC™) technology.

    Under the terms of the agreement, the companies will engage in a three-year discovery program. Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells. Up to two joint programs will be mutually selected for further development and commercialization, with each partner sharing 50 percent of costs and profits. Each company will lead development, regulatory and commercialization activities for one of the joint programs. In addition, the agreement allows for each partner to pursue up to two programs independently, with a mid-to high-single digit percent royalty payable on net sales. Atreca and Xencor began working together in 2019 under a material transfer agreement to accelerate this new collaboration agreement.

    "We are proud to be partnering with Xencor, a leader in the engineering and development of antibody therapeutics," said John A. Orwin, Chief Executive Officer of Atreca. "We believe this collaboration leverages two approaches with the potential to be highly complementary and underscores the value of novel antibody-target pairs in the development of cancer therapeutics. We are encouraged by the work already completed under our initial agreement and look forward to a productive partnership, as well as the prospect of adding T cell-engaging bispecific product candidates to our clinical pipeline."

    "Xencor is building a broad portfolio of drug candidates based on our XmAb technologies, which enable us to create therapeutic antibodies and other proteins with enhanced properties and new mechanisms of action," said Bassil Dahiyat, Ph.D., President and Chief Executive Officer at Xencor. "Atreca's unique discovery platform complements our protein engineering capabilities and bispecific platform by providing novel, tumor-selective antibodies and targets to engage with cytotoxic T cell killing. This collaboration offers both Xencor and Atreca with several opportunities to advance novel first-in-class CD3 bispecific antibodies for the potential treatment of patients with cancer."

    About XmAb® Bispecific Fc Technology and CD3 Bispecific Antibodies

    XmAb® bispecific Fc domains enable the rapid design and simplified development of bispecific antibodies, and other protein structures, that can bind two or more different targets simultaneously using an engineered heterodimer Fc domain. CD3 bispecific antibodies contain an anti-tumor associated antigen binding domain and a second binding domain targeted to CD3, an activating receptor on T cells, with the goal to recruit or activate T cells against the antigen target. Xencor has developed a mixed valency format, the XmAb 2+1 bispecific antibody, with two domains that bind a tumor target, which preferentially may bind and kill tumor cells with high target expression while potentially sparing low-expression normal tissues.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    About Xencor, Inc.

    Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 17 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

    Atreca Forward-Looking Statements

    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the potential to add T-cell engaging bispecific product candidates to our clinical pipeline, the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will", "believe," "potential," "prospect," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Xencor Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of applicable securities laws, including, but not limited to, the quotations from Xencor's president and chief executive officer and any expectations relating to future product candidates and Xencor's research and development programs. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor's public securities filings. For a discussion of these and other factors, please refer to Xencor's annual report on Form 10-K for the year ended December 31, 2019 as well as Xencor's subsequent filings with the Securities and Exchange Commission. All forward-looking statements are based on Xencor's current information and belief as well as assumptions made by Xencor. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

    Immune Repertoire Capture® is a registered trademark of Atreca, Inc.

    XmAb® is a registered trademark of Xencor, Inc.

    Atreca Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com



    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Xencor Contacts

    Xencor, Inc.

    Charles Liles

    626-737-8118

    cliles@xencor.com

    Media Contact:

    Jason I. Spark

    Canale Communications

    619-849-6005

    jason@canalecomm.com

    Primary Logo

    View Full Article Hide Full Article
  23. SOUTH SAN FRANCISCO, Calif., June 11, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that members of the company's management team will host a webinar to present preclinical data on Atreca's lead product candidate, ATRC-101, on Monday, June 15, 2020, at 4:30 p.m. EDT.

    The program will include new data regarding the novel target and mechanism of action of ATRC-101, as well as an overview of ongoing and planned clinical studies. 

    ATRC-101 Webinar Information
    The live webinar can be accessed through the Events & Presentations section…

    SOUTH SAN FRANCISCO, Calif., June 11, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that members of the company's management team will host a webinar to present preclinical data on Atreca's lead product candidate, ATRC-101, on Monday, June 15, 2020, at 4:30 p.m. EDT.

    The program will include new data regarding the novel target and mechanism of action of ATRC-101, as well as an overview of ongoing and planned clinical studies. 

    ATRC-101 Webinar Information

    The live webinar can be accessed through the Events & Presentations section of the Company's website at https://ir.atreca.com/news-and-events/event-calendar. An archived replay of the webcast will be available on the Company's website for 90 days following the live event.

    About ATRC-101

    ATRC-101 is a monoclonal antibody derived from an antibody identified using Atreca's discovery platform. ATRC-101 is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology. This mechanism involves systemic delivery of an antibody that has been shown in preclinical models to engage the innate immune system, cause remodeling of the tumor microenvironment and drive T cell-mediated destruction of tumor cells. Atreca has identified the target of ATRC-101 as a ribonucleoprotein (RNP) complex. Underlining the rationale for human testing, ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical syngeneic tumor models, including one model in which PD-1 checkpoint inhibitors typically display limited activity. Further, ATRC-101 has been shown to react in vitro with a majority of human ovarian, non-small cell lung, colorectal, breast cancers and acral melanoma samples from multiple patients.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will", "believe," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com

    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  24. SOUTH SAN FRANCISCO, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Kristine M. Ball to the company's Board of Directors. Ms. Ball brings more than 25 years of life sciences industry experience focused primarily on finance, corporate development and strategic planning.

    "We are pleased to announce the appointment of Kristine to our board of directors," said John A. Orwin, Chief Executive Officer of Atreca. "Kristine brings a wealth of expertise gained over her career in the life sciences industry, during which…

    SOUTH SAN FRANCISCO, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Kristine M. Ball to the company's Board of Directors. Ms. Ball brings more than 25 years of life sciences industry experience focused primarily on finance, corporate development and strategic planning.

    "We are pleased to announce the appointment of Kristine to our board of directors," said John A. Orwin, Chief Executive Officer of Atreca. "Kristine brings a wealth of expertise gained over her career in the life sciences industry, during which she established a track record of executing on effective financing and corporate development strategies to help build successful companies. She will be a valuable asset to Atreca as we continue to develop our lead product candidate, ATRC-101, and begin to advance additional candidates into the clinic."

    Ms. Ball most recently served as Senior Vice President (SVP) of Corporate Strategy and Chief Financial Officer (CFO) of Menlo Therapeutics, Inc., a publicly traded biopharmaceutical company. Prior to joining Menlo in 2017, Ms. Ball served as SVP and CFO of Relypsa, Inc., where she helped raise over $675 million in various equity and debt financings and co-led the cross-functional teams responsible for closing partnerships with Sanofi and Vifor Fresenius Medical Care Renal Pharma, as well as the company's acquisition by Galenica. Prior to Relypsa, Ms. Ball previously served as SVP, Finance and Administration and CFO of KAI Pharmaceuticals, Inc. (acquired by Amgen) and Vice President, Finance at Exelixis, Inc. Before joining Exelixis, Ms. Ball was a senior manager in Ernst & Young's life sciences audit practice. Ms. Ball holds a B.S. from Babson College. She also served on the Board of Directors of Forty Seven Inc. prior to the company's recent acquisition by Gilead.

    "Atreca's differentiated discovery platform has shown the ability to generate novel and potentially efficacious therapeutics for the treatment of large groups of patients in oncology," said Ms. Ball. "I am excited to join the team during an important phase for a growing company and I very much look forward to being a part of Atreca's continued progress and success."

    About Atreca, Inc.
    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will," "potential," "continue," "begin," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts

    Atreca, Inc.
    Herb Cross
    Chief Financial Officer
    info@atreca.com

    Investors:
    Alex Gray, 650-779-9251
    agray@atreca.com

    Media:
    Sheryl Seapy, 213-262-9390
    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  25. SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the first quarter ended March 31, 2020, and provided an overview of recent developments.

    "While the COVID-19 pandemic has presented unexpected challenges, we continue to execute on our pipeline and business strategy, and we look forward to further progress throughout 2020," said John Orwin, Chief Executive Officer. "Patients continue to be enrolled and treated in our Phase 1b dose-escalation clinical trial evaluating ATRC-101…

    SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the first quarter ended March 31, 2020, and provided an overview of recent developments.

    "While the COVID-19 pandemic has presented unexpected challenges, we continue to execute on our pipeline and business strategy, and we look forward to further progress throughout 2020," said John Orwin, Chief Executive Officer. "Patients continue to be enrolled and treated in our Phase 1b dose-escalation clinical trial evaluating ATRC-101 in multiple solid tumors. In addition, we believe our recently announced alliance with BeiGene and IGM Biosciences to help address the COVID-19 pandemic underscores the potential of our differentiated discovery platform, and we are working closely with our partners to advance research and development as quickly as possible."

    Recent Developments and Highlights

    • In February 2020, Atreca commenced patient dosing in a Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers. Patient screening continues in the study and, to date, three subjects have been enrolled in the first dose cohort. The ongoing COVID-19 pandemic is likely to impact our ability to initiate additional clinical trial sites quickly, which may ultimately result in enrollment delays.
       
    • Atreca announced a collaboration with BeiGene, Ltd. and IGM Biosciences, Inc. to discover and develop a novel antibody treatment for COVID-19. The alliance will utilize Atreca's proprietary discovery platform to generate the sequences of antibodies made by particular B cells found in blood obtained from acutely infected COVID-19 patients.

    Upcoming Milestone

    • Atreca will present a trial-in-progress poster at the upcoming American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program being held from May 29 to May 31, 2020. The poster will describe the design of Atreca's ongoing Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers.

    First Quarter 2020 Financial Results

    • As of March 31, 2020, cash, cash equivalents and investments totaled $166.3 million.
       
    • Research and development expenses for the three months ended March 31, 2020 were $14.2 million, including non-cash share-based compensation expense of $1.1 million.
       
    • General and administrative expenses for the three months ended March 31, 2020 were $7.1 million, including non-cash share-based compensation expense of $1.4 million.
       
    • Atreca reported a net loss of $20.4 million, or basic and diluted net loss per share attributable to common stockholders of $0.73, for the three months ended March 31, 2020.

    About Atreca, Inc.
    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumor. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements
    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "believe," "likely," "may," "will," "forward," "potential," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

     
    Atreca, Inc.
    Condensed Consolidated Balance Sheets
    (in thousands, except share and per share data)
             
        March 31,   December 31, 
        2020   2019
             
    ASSETS                
                     
    Current Assets              
    Cash and cash equivalents   $ 92,183     $ 157,954  
    Investments     58,880       14,663  
    Prepaid expenses and other current assets     3,147       3,502  
    Total current assets     154,210       176,119  
    Property and equipment, net     6,632       5,771  
    Long-term investments     15,229       10,799  
    Deposits and other     2,898       3,026  
    Total assets   $ 178,969     $ 195,715  
                     
    LIABILITIES AND STOCKHOLDERS' EQUITY                
                     
    Current Liabilities                
    Accounts payable   $ 2,378     $ 2,133  
    Accrued expenses     2,930       5,395  
    Other current liabilities     1,549       419  
    Total current liabilities     6,857       7,947  
    Capital lease obligations, net of current portion     41       53  
    Deferred rent     1,431       763  
    Other non-current liabilities     505       -  
    Total liabilities     8,834       8,763  
                     
                     
    Stockholders' equity                
    Common stock     3       3  
    Additional paid-in capital     354,477       351,039  
    Accumulated other comprehensive loss     179       16  
    Accumulated deficit     (184,524 )     (164,106 )
    Total stockholders' equity     170,135       186,952  
    Total liabilities and stockholders' equity   $ 178,969     $ 195,715  
             


     
    Atreca, Inc.
    Condensed Consolidated Statements of Operations
    (in thousands, except share and per share data)
    (unaudited)
               
          Three Months Ended
          March 31,
          2020   2019
    Expenses        
      Research and development   $ 14,210     $ 11,713  
      General and administrative     7,123       2,518  
      Total expenses     21,333       14,231  
    Interest and other income (expense)        
      Other income     231       165  
      Interest income     685       545  
      Interest expense     (1 )     (2 )
      Preferred stock warrant liability revaluation           (50 )
      Loss on disposal of property and equipment           (5 )
    Loss before Income tax expense     (20,418 )     (13,578 )
    Income tax benefit (expense)           (1 )
    Net loss   $ (20,418 )   $ (13,579 )
    Net loss per share, basic and diluted   $ (0.73 )   $ (6.40 )
    Weighted-average shares used in computing        
    net loss per share, basic and diluted     28,020,408       2,120,925  
               

    Contacts
    Atreca, Inc.
    Herb Cross
    Chief Financial Officer
    info@atreca.com 

    Investors:
    Alex Gray, 650-779-9251
    agray@atreca.com

    Media:
    Sheryl Seapy, 213-262-9390
    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  26. SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that a trial in progress poster will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program being held from May 29 to May 31, 2020. The poster will describe the design of the company's ongoing Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers.

    Details of Atreca's poster presentation:

    Abstract Title: First-in-human Phase 1b study of ATRC-101, an engineered…

    SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that a trial in progress poster will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program being held from May 29 to May 31, 2020. The poster will describe the design of the company's ongoing Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers.

    Details of Atreca's poster presentation:

    Abstract Title: First-in-human Phase 1b study of ATRC-101, an engineered version of a patient-derived antibody targeting a tumor-restricted ribonucleoprotein complex.

    Session Title: Developmental Therapeutics – Immunotherapy

    The abstract can be found on the ASCO website and the poster will be made available on the company's website once the virtual program begins on Friday, May 29 at 8:00 a.m. EDT.

    About ATRC-101
    ATRC-101 is a monoclonal antibody derived from an antibody identified using Atreca's discovery platform. ATRC-101 is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology. This mechanism involves systemic delivery of an antibody that has been shown in preclinical models to engage the innate immune system, cause remodeling of the tumor microenvironment and drive T cell-mediated destruction of tumor cells. Atreca has identified the target of ATRC-101 as a ribonucleoprotein (RNP) complex. Underlining the rationale for human testing, ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical syngeneic tumor models, including one model in which PD-1 checkpoint inhibitors typically display limited activity. Further, ATRC-101 has been shown to react in vitro with a majority of human ovarian, non-small cell lung, colorectal, breast cancers and acral melanoma samples from multiple patients.

    About Atreca, Inc.
    Atreca is a biopharmaceutical company developing novel antibody-based cancer immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumor. These antibodies provide the basis for first-in-class therapeutic candidates, such as lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.  

    Forward-Looking Statements
    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will", "believe," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts
    Atreca, Inc.
    Herb Cross
    Chief Financial Officer
    info@atreca.com

    Investors:
    Alex Gray, 650-779-9251
    agray@atreca.com

    Media:
    Sheryl Seapy, 213-262-9390
    sseapy@w2ogroup.com
    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  27. SOUTH SAN FRANCISCO, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that management will participate in a fireside chat at the 2020 RBC Capital Markets Virtual Global Healthcare Conference on Tuesday, May 19, at 11:30 a.m. EDT.

    A live audio webcast of the presentation can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. An archived replay of the webcast will be available on the Company's website for 90 days following the live presentation.

    About Atreca, Inc.
    Atreca is a biopharmaceutical…

    SOUTH SAN FRANCISCO, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that management will participate in a fireside chat at the 2020 RBC Capital Markets Virtual Global Healthcare Conference on Tuesday, May 19, at 11:30 a.m. EDT.

    A live audio webcast of the presentation can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. An archived replay of the webcast will be available on the Company's website for 90 days following the live presentation.

    About Atreca, Inc.
    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumor. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Contacts
    Atreca, Inc.
    Herb Cross
    Chief Financial Officer
    info@atreca.com

    Investors:
    Alex Gray, 650-779-9251
    agray@atreca.com

    Media:
    Sheryl Seapy, 213-262-9390
    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  28. - Companies to utilize proprietary platforms to discover, develop, and manufacture potential therapeutic antibodies to combat ongoing COVID-19 pandemic -

    SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass. and BEIJING, China and MOUNTAIN VIEW, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (NASDAQ:BCEL), BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), and IGM Biosciences, Inc. (NASDAQ:IGMS), today announced their plans to collaborate to help address the COVID-19 pandemic. The companies will leverage their combined technology and expertise in an effort to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. Given the urgency of the global COVID-19 pandemic, the parties…

    - Companies to utilize proprietary platforms to discover, develop, and manufacture potential therapeutic antibodies to combat ongoing COVID-19 pandemic -

    SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass. and BEIJING, China and MOUNTAIN VIEW, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (NASDAQ:BCEL), BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), and IGM Biosciences, Inc. (NASDAQ:IGMS), today announced their plans to collaborate to help address the COVID-19 pandemic. The companies will leverage their combined technology and expertise in an effort to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. Given the urgency of the global COVID-19 pandemic, the parties have agreed to begin work immediately and plan to finalize financial details and other terms in the future. 

    Immunoglobulin M (IgM) and immunoglobulin A (IgA) are classes of antibodies naturally produced by the human immune system and are differentiated from immunoglobulin G (IgG) antibodies in part by their greater number of binding domains (IgM: 10, IgA: 4, IgG: 2). IGM Biosciences engineers IgM and IgA antibodies with greater binding power per antibody, relative to comparable IgG antibodies. This greater binding power could potentially result in better activity against a broader range of variants of the virus which causes COVID-19, as compared to traditional IgG antibodies. IgA and IgM antibodies also have the inherent property of active transport from the blood stream to mucosal surfaces, such as in the lung, which may provide a therapeutic advantage for respiratory diseases such as COVID-19. 

    The alliance will utilize Atreca's proprietary discovery platform to generate the sequences of antibodies made by particular B cells found in blood obtained from acutely infected COVID-19 patients. IGM's technology platform will then be leveraged in an effort to develop and manufacture engineered IgM and IgA therapeutic antibodies from the identified sequences.

    BeiGene has agreed to provide global clinical development support by leveraging its more than 1,100-person global development team across China, the United States, Europe, and Australia, including leading global regulatory interactions for any potential drug candidate that is developed. BeiGene is a leader in global clinical development with 26 potentially registration-enabling trials ongoing and over 60 studies enrolling patients in more than 35 countries. Its large, global clinical development team is focused on high-quality, efficient drug development optimized for global regulatory submissions.

    Atreca and IGM have entered into a Material Transfer and Collaboration Agreement to enable the parties to begin working together immediately. Atreca, IGM, and BeiGene plan to discuss further terms and arrangements in the future. If research, manufacturing, and regulatory activities proceed very well, then the companies believe that an antibody may be ready to begin clinical testing in the first half of 2021.

    "Atreca has a history of successfully generating potent, neutralizing antibodies against a number of infectious disease pathogens, and we are proud to join BeiGene and IGM in working to identify a potential therapy to help address this unprecedented international health crisis," said John Orwin, Chief Executive Officer of Atreca. "We believe our discovery platform is uniquely positioned to rapidly isolate a broad range of relevant antibody sequences from COVID-19 patients that can then be used to create potentially effective targeted therapies. We have begun processing samples obtained from acutely infected COVID-19 patients and are focused on analyzing single plasmablast B cells isolated from these samples to identify antibodies targeting potentially novel epitopes that may be missed by other approaches that rely on a specific viral protein to select B cells."

    "Helping patients is core to our mission, and we believe IGM may be the only company in the world that is currently positioned to produce IgM and IgA antibodies with high yield and high quality," said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. "As such, we feel that we have a responsibility to explore the utility of these antibodies in COVID-19 patients. We believe that IgM and IgA antibodies created from sequences identified with Atreca's platform may produce better binding, cross-reactivity, neutralization, and mucosal transport than the corresponding IgG antibodies. These characteristics, plus IGM's ability to efficiently manufacture IgM and IgA antibodies, gives us confidence in the collaboration and hope that we may develop a product that will be of significant benefit to public health."

    "While the COVID-19 pandemic has presented new challenges to the biotechnology and pharmaceutical industries, equally notable is the desire for international scientific collaboration and cooperation," said John V. Oyler, Co-Founder, Chief Executive Officer, and Chairman of BeiGene. "We are grateful for the opportunity to lend our global clinical development resources to this critical cause, with both Atreca and IGM to leverage their innovative discovery and development platforms in an effort to combat COVID-19."

    Atreca's proprietary discovery platform, including its Immune Repertoire Capture® (IRC™) technology, generates bias- and error-corrected, natively paired heavy and light chain sequences of the antibodies expressed by single plasmablast B cells isolated from patient blood samples, enabling analyses of patient antibody repertoires generated in an active immune response in a target agnostic fashion, and permitting selection of antibody sequences for immediate gene synthesis and expression. IGM's proprietary platform expands upon the inherent characteristics of IgM and IgA antibodies and enables the rapid development of engineered therapeutics. IGM's technology allows it to create IgM and IgA antibodies with higher affinity and avidity than naturally occurring IgM and IgA antibodies, and the company has also overcome the historical difficulties in recombinantly expressing and manufacturing IgM and IgA antibodies.

    About Atreca, Inc.
    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumor. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    About BeiGene
    BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,500+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. BeiGene currently markets two internally-discovered oncology products: BTK inhibitor BRUKINSA™ (zanubrutinib) in the United States, and anti-PD-1 antibody tislelizumab in China. BeiGene also markets or plans to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com.

    About IGM Biosciences, Inc.
    Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

    Atreca Forward-Looking Statements
    This release contains forward-looking statements regarding Atreca's strategy and future plans, including statements regarding the anticipated isolation of relevant antibody sequences from COVID-19 patients using Atreca's proprietary discovery platform, the development of ATRC-101 and Atreca's clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "plan," "will," "believe," "may," "future," "potential" and similar words, although some forward-looking statements are expressed differently. Atreca's actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of its research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in Atreca's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Atreca undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

    BeiGene Forward-Looking Statements
    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene's plans to work together with Atreca and IGM in the development of a novel IgM or IgA antibody targeting SARS-CoV-2 for the potential treatment of COVID-19, the services to be provided by BeiGene, and the parties' efforts to finalize further terms and arrangements in the future.  Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including the ability of Atreca, BeiGene and IGM to discover, develop and manufacture a novel IgM or IgA antibody targeting SARS-CoV-2 for the treatment of COVID-19; the risk that Atreca, BeiGene or IGM decide not to pursue the collaboration or that the parties are unable to agree to further terms and arrangements for the collaboration in the future; the risk that the potential benefits of the collaboration do not materialize or do not outweigh the costs; BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene's limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the COVID-19 pandemic on BeiGene's clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled "Risk Factors" in BeiGene's most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

    IGM Cautionary Note Regarding Forward-Looking Statements
    This press release contains forward-looking statements.  These statements include, but are not limited to, statements relating to the contemplated collaboration among IGM, Atreca and BeiGene; the possible nature and scope of any such collaboration; the capabilities of IGM's technology platform, both generally and specifically with respect to development, testing and manufacture of antibodies targeted at COVID- 19; the potential safety and efficacy of such antibodies; and the capabilities of Atreca and BeiGene.

    Such statements are subject to numerous important risks and uncertainties that may cause actual events or results to differ materially, including, but not limited to, the risks that: IGM, Atreca and/or Beigene ultimately decide to not pursue the collaboration; IGM, Atreca and BeiGene do not reach agreement on the definitive terms and conditions of such collaboration; one or more of IGM, Atreca, BeiGene decide to leave the collaboration; antibodies with the desired characteristics cannot be isolated from the COVID-19 patient samples obtained by Atreca;  any antibodies developed are not safe and effective in treating COVID - 19; such antibodies are not safer and/or more effective than alternatives to treating or otherwise addressing COVID – 19; IGM is not able to successfully manufacture such antibodies; any preclinical studies and clinical trials do not proceed successfully; all necessary regulatory approvals cannot be obtained; the potential benefits of the collaboration and these efforts do not outweigh their costs; the collaboration and related efforts are delayed or disrupted by the COVID-19 pandemic itself  or by governmental responses to the pandemic; and other risks and uncertainties, including those more fully described in IGM's filings with the Securities and Exchange Commission ("SEC"), including IGM's Annual Report on Form 10-K filed with the SEC on March 26, 2020 and in IGM's future reports to be filed with the SEC.  Any forward-looking statements contained in this press release speak only as of the date hereof, and IGM specifically disclaims any obligation to update any forward-looking statement, except as required by law.

    Atreca Contact:

    Herb Cross
    Chief Financial Officer
    info@atreca.com 

    Atreca Investor Contact:

    Alex Gray
    +1 650-779-9251
    agray@atreca.com 

    Atreca Media Contact:

    Sheryl Seapy
    +1 213-262-9390
    sseapy@w2ogroup.com 

    BeiGene Investor Contact:

    Craig West
    +1 857-302-5189
    ir@beigene.com 

    BeiGene Media Contact:

    Liza Heapes or Vivian Ni
    +1 857-302-5663 or +1 857-302-7596
    media@beigene.com               

    IGM Biosciences Contact:

    Argot Partners
    David Pitts
    +1 212-600-1902
    igmbio@argotpartners.com

     

    Primary Logo

    View Full Article Hide Full Article
  29. SOUTH SAN FRANCISCO, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in two upcoming investor conferences:

    Canaccord Genuity Horizons in Oncology Virtual Event
    Wednesday, April 8, 2020
    Panel time: 12:45 p.m. EDT

    19th Annual Needham Virtual Healthcare Conference
    Wednesday, April 15, 2020
    Presentation time: 2:50 p.m. EDT

    Live webcasts of each event can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. Archived replays of the webcasts will be available…

    SOUTH SAN FRANCISCO, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in two upcoming investor conferences:

    Canaccord Genuity Horizons in Oncology Virtual Event

    Wednesday, April 8, 2020

    Panel time: 12:45 p.m. EDT

    19th Annual Needham Virtual Healthcare Conference

    Wednesday, April 15, 2020

    Presentation time: 2:50 p.m. EDT

    Live webcasts of each event can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. Archived replays of the webcasts will be available on the Company's website for 90 days following the live presentations.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based cancer immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumor. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    info@atreca.com

    Investors:

    Alex Gray, 650-779-9251

    agray@atreca.com

    Media:

    Sheryl Seapy, 213-262-9390

    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  30. SOUTH SAN FRANCISCO, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the fourth quarter and full year ended December 31, 2019 and provided an overview of recent developments.

    "2019 was a successful year for Atreca as we evolved into a public, clinical-stage company, positioning us for future growth," said John Orwin, Chief Executive Officer. "We recently dosed the first patient in our Phase 1b dose-escalation clinical trial evaluating ATRC-101 in multiple solid tumor types following clearance…

    SOUTH SAN FRANCISCO, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the fourth quarter and full year ended December 31, 2019 and provided an overview of recent developments.

    "2019 was a successful year for Atreca as we evolved into a public, clinical-stage company, positioning us for future growth," said John Orwin, Chief Executive Officer. "We recently dosed the first patient in our Phase 1b dose-escalation clinical trial evaluating ATRC-101 in multiple solid tumor types following clearance of our first IND by the FDA in November. Additionally, our new strategic collaboration with Merck to identify novel antibody targets in oncology underscores the potential of our differentiated approach to drug discovery and could help accelerate efforts to expand our clinical pipeline. We look forward to further progress in 2020."

    Recent Developments and Highlights

    • Following the clearance of an Investigational New Drug application (IND) by the U.S. Food and Drug Administration (FDA) in November 2019, Atreca commenced patient dosing in a Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers.
       
    • In February 2020, Atreca announced a strategic research collaboration with Merck to identify the antigenic targets of select novel antibodies discovered by Atreca with potential utility in oncology. Under the terms of the agreement, Atreca retains exclusive ownership and rights to develop all Atreca antibodies included in the collaboration with Merck, while Merck will receive a right-of-first negotiation should Atreca seek to partner or out-license one or more of the antibodies.

    Fourth Quarter and Full Year 2019 Financial Results

    • As of December 31, 2019, cash and cash equivalents and short-term investments totaled $183.4 million.
       
    • Research and development expenses for the year ended December 31, 2019 were $54.7 million, including non-cash share-based compensation expense of $3.0 million. Research and development expenses for the three months ended December 31, 2019 were $14.3 million, including non-cash share-based compensation expense of $886,000.
       
    • General and administrative expenses for the year ended December 31, 2019 were $17.8 million, including non-cash share-based compensation expense of $3.1 million. General and administrative expenses for the three months ended December 31, 2019 were $6.9 million, including non-cash share-based compensation expense of $1.2 million.
       
    • Atreca reported a net loss of $67.5 million, or basic and diluted net loss per share attributable to common stockholders of $4.26, for the year ended December 31, 2019. The Company reported a net loss of $20.1 million, or basic and diluted net loss per share attributable to common stockholders of $0.72, for the three months ended December 31, 2019.

    About Atreca, Inc.
    Atreca is a biopharmaceutical company developing novel antibody-based cancer immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumor. These antibodies provide the basis for first-in-class therapeutic candidates, such as lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.  

    Forward-Looking Statements
    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will", "could," "future," "forward," "potential," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Atreca, Inc.
    Condensed Consolidated Balance Sheets
    (in thousands, except share and per share data)

           
      December 31, December 31, 
        2019       2018  
           
    ASSETS      
           
    Current Assets
    Cash and cash equivalents $ 157,954     $ 114,504  
    Investments   14,663        —  
    Prepaid expenses and other current assets   3,502       2,721  
    Total current assets   176,119       117,225  
    Property and equipment, net   5,771       4,143  
    Long-term Investments   10,799        —  
    Deposits and other   3,026       316  
    Total assets $ 195,715     $ 121,684  
           
    LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
           
    Current Liabilities
    Accounts payable $ 2,133     $ 1,307  
    Accrued expenses   5,395       3,008  
    Other current liabilities   419       247  
    Total current liabilities   7,947       4,562  
    Capital lease obligations, net of current portion   53       100  
    Deferred rent   763       6  
    Preferred stock warrant liability   -       380  
    Total liabilities   8,763       5,048  
           
    Convertible preferred stock    —       209,669  
           
    Stockholders' equity (deficit)
    Common stock   3        —  
    Additional paid-in capital   351,039       3,593  
    Accumulated other comprehensive loss   16       (4 )
    Accumulated deficit   (164,106 )     (96,622 )
    Total stockholders' equity   186,952       (93,032 )
    Total liabilities and stockholders' equity (deficit) $ 195,715     $ 121,684  
           


    Atreca, Inc.
    Condensed Consolidated Statements of Operations
    (in thousands, except share and per share data)
    (unaudited)

    ($ amounts in 000's, except per share amounts)              
                     
        Three Months Ended   Twelve Months Ended
        December 31,   December 31,
          2019       2018       2019       2018  
    Expenses              
      Research and development $ 14,279     $ 10,631     $ 54,726     $ 32,513  
      General and administrative   6,926       2,253       17,845       7,060  
      Total expenses   21,205       12,884       72,571       39,573  
    Interest and other income (expense)              
      Other income   329       301       2,134       961  
      Interest income   885       602       3,213       714  
      Interest expense   (1 )     (2 )     (6 )     (9 )
      Preferred stock warrant liability revaluation    —       (3 )     (123 )     (33 )
      Foreign exchange loss   (7 )      —       (8 )      —  
      Loss on disposal of property and equipment   (115 )      —       (122 )     (1 )
    Loss before Income tax expense   (20,114 )     (11,986 )     (67,483 )     (37,941 )
    Income tax benefit (expense)   1       2       (1 )     1  
    Net loss $ (20,113 )   $ (11,984 )   $ (67,484 )   $ (37,940 )
    Net loss per share, basic and diluted $ (0.72 )   $ (5.64 )   $ (4.26 )   $ (18.02 )
    Weighted-average shares used in computing              
    net loss per share, basic and diluted   27,959,975       2,125,315       15,834,175       2,104,861  
                     

     


    Contacts
    Atreca, Inc.
    Herb Cross
    Chief Financial Officer
    info@atreca.com

    Investors:
    Alex Gray, 650-779-9251, ext. 251
    agray@atreca.com

    Media:
    Sheryl Seapy, 213-262-9390
    sseapy@w2ogroup.com
    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  31. SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that John Orwin, Chief Executive Officer, will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020, at 4:50 p.m. EST. The conference will be held at the Boston Marriott Copley Place in Boston, Massachusetts.  

    A live audio webcast of the presentation can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. An archived replay of the webcast will be available on the Company's…

    SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that John Orwin, Chief Executive Officer, will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020, at 4:50 p.m. EST. The conference will be held at the Boston Marriott Copley Place in Boston, Massachusetts.  

    A live audio webcast of the presentation can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. An archived replay of the webcast will be available on the Company's website for 90 days following the live presentation.

    About Atreca, Inc.
    Atreca is a biopharmaceutical company developing novel antibody-based cancer immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumor. These antibodies provide the basis for first-in-class therapeutic candidates, such as lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Contacts

    Atreca, Inc.
    Herb Cross
    Chief Financial Officer
    info@atreca.com

    Investors:
    Alex Gray, 650-779-9251
    agray@atreca.com

    Media:
    Sheryl Seapy, 213-262-9390
    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  32. SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the first patient has been dosed in a Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers. ATRC-101, a monoclonal antibody derived from a human antibody identified in a cancer patient via Atreca's drug discovery platform, targets a ribonucleoprotein (RNP) complex and is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology.

    "Dosing of the first patient in our Phase…

    SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the first patient has been dosed in a Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers. ATRC-101, a monoclonal antibody derived from a human antibody identified in a cancer patient via Atreca's drug discovery platform, targets a ribonucleoprotein (RNP) complex and is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology.

    "Dosing of the first patient in our Phase 1b study of ATRC-101 is an important milestone marking our transition to a clinical-stage company," said John Orwin, Chief Executive Officer. "ATRC-101 has demonstrated potent single-agent anti-tumor activity in multiple preclinical solid tumor models and we believe, through both its novel target and mechanism of action, that this antibody represents an exciting potential new approach in oncology. We look forward to reporting initial data from this study in the second half of 2020."

    The Phase 1b open-label, dose escalation, monotherapy trial with an adaptive 3+3 design will enroll patients with colorectal, ovarian, non-small cell lung and breast cancers and acral melanoma. Over 50% of tumor tissue samples evaluated by Atreca in each of these cancer types were positive for the antigenic target of ATRC-101, an RNP complex. Major objectives of the trial are to characterize the safety of ATRC-101 and determine a recommended dose for future studies. The trial will also evaluate potential biomarkers and initial signals of clinical activity of ATRC-101. Upon confirmation of safety, Atreca plans to test ATRC-101 further as a single agent and in combination with checkpoint inhibitors and select chemotherapeutics.

    For more information about the clinical trial design please visit www.clinicaltrials.gov (NCT04244552).

    About ATRC-101
    ATRC-101 is a monoclonal antibody derived from an antibody identified using Atreca's discovery platform. ATRC-101 is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology. This mechanism involves systemic delivery of an antibody that has been shown in preclinical models to engage the innate immune system, cause remodeling of the tumor microenvironment and drive T cell-mediated destruction of tumor cells. Atreca has identified the target of ATRC-101 as a ribonucleoprotein (RNP) complex. Underlining the rationale for human testing, ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical syngeneic tumor models, including one model in which PD-1 checkpoint inhibitors typically display limited activity. Further, ATRC-101 has been shown to react in vitro with a majority of human ovarian, non-small cell lung, colorectal, breast cancers and acral melanoma samples from multiple patients.

    About Atreca, Inc.
    Atreca is a biopharmaceutical company developing novel antibody-based cancer immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumor. These antibodies provide the basis for first-in-class therapeutic candidates, such as lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements
    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will", "believe," "potential," "plans," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our prospectus, dated June 19, 2019, as filed with the Securities and Exchange Commission (SEC) pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, which are available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts
    Atreca, Inc.
    Herb Cross
    Chief Financial Officer
    info@atreca.com

    Investors:
    Alex Gray, 650-779-9251
    agray@atreca.com

    Media:
    Sheryl Seapy, 213-262-9390
    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  33. SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it has entered into a strategic research collaboration with Merck (known as MSD outside the United States and Canada), to identify the antigenic targets of select antibodies discovered by Atreca with potential utility in oncology.

    "We are excited to collaborate with Merck, a global leader in oncology, to identify novel antibody targets that may hold the potential to transform the future treatment of cancer," said John Orwin, Chief Executive…

    SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it has entered into a strategic research collaboration with Merck (known as MSD outside the United States and Canada), to identify the antigenic targets of select antibodies discovered by Atreca with potential utility in oncology.

    "We are excited to collaborate with Merck, a global leader in oncology, to identify novel antibody targets that may hold the potential to transform the future treatment of cancer," said John Orwin, Chief Executive Officer. "To date, our differentiated discovery platform has yielded over 1,600 antibodies that bind selectively to non-autologous tumor tissue. We are pleased Merck has recognized the potential of our differentiated discovery platform to deliver novel antibody-target pairs in oncology and will be working with us to elucidate the antigenic targets of certain antibodies we have generated from active human immune responses, accelerating our drug development efforts. We look forward to a highly productive collaboration."

    The antibodies included in the collaboration agreement will be selected by Atreca based on mutually agreed criteria and other considerations. Under the terms of the agreement, Atreca will receive an upfront cash payment and retain exclusive ownership and rights to develop all Atreca antibodies included in the collaboration with Merck, while Merck will receive a right-of-first-negotiation should Atreca seek to partner or out-license one or more of these antibodies. Following target identification, both companies will have freedom to advance therapeutic candidates against the target(s) identified under the collaboration, with development and commercial milestones payable by either party.

    About Atreca, Inc.
    Atreca is a biopharmaceutical company developing novel antibody-based cancer immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumor. These antibodies provide the basis for first-in-class therapeutic candidates, such as ATRC-101, with the potential to address unmet need in large groups of cancer patients. The IND for ATRC-101, the company's lead product candidate, has been cleared by the FDA and a Phase 1b study in multiple solid tumor cancers is expected to commence in early 2020. For more information on Atreca, please visit www.atreca.com

    Forward-Looking Statements
    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our research, development and clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will", "expect," "believe," "potential," "continue," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our prospectus, dated June 19, 2019, as filed with the Securities and Exchange Commission (SEC) pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, which are available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts
    Atreca, Inc.
    Herb Cross
    Chief Financial Officer
    info@atreca.com

    Investors:
    Alex Gray, 650-779-9251
    agray@atreca.com

    Media:
    Sheryl Seapy, 213-262-9390
    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  34. First IND clearance of a clinical candidate derived from Atreca's differentiated drug discovery platform

     Phase 1b clinical trial in patients with solid tumors to begin in early 2020

    REDWOOD CITY, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application. Atreca expects to initiate a first-in-human Phase 1b clinical trial of ATRC-101 in patients with solid tumors in early 2020.

    "The FDA's clearance of our…

    First IND clearance of a clinical candidate derived from Atreca's differentiated drug discovery platform

     Phase 1b clinical trial in patients with solid tumors to begin in early 2020

    REDWOOD CITY, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application. Atreca expects to initiate a first-in-human Phase 1b clinical trial of ATRC-101 in patients with solid tumors in early 2020.

    "The FDA's clearance of our IND application for ATRC-101 is a significant milestone for Atreca and validates the ability of our differentiated drug discovery platform to generate novel clinical candidates against cancer," said John Orwin, Chief Executive Officer. "We believe that ATRC-101, with both its unique target and mechanism of action, represents an exciting approach in oncology, and we look forward to the initiation of our Phase 1b clinical trial in early 2020."

    The Phase 1b trial will be an open-label, dose escalation, monotherapy trial with an adaptive 3+3 design and will enroll patients with a variety of solid tumor cancers, including ovarian, non-small cell lung, colorectal, breast and acral melanoma. The antigenic target of ATRC-101, a ribonucleoprotein complex, is expressed on over 50% of patient samples for each of these tumor types. Major objectives for the trial are to characterize the safety of ATRC-101 and determine a recommended dose for future studies. The trial will also evaluate potential biomarkers and the initial clinical activity of ATRC-101.

    About ATRC-101
    ATRC-101 is a monoclonal antibody derived from an antibody identified using Atreca's discovery platform. ATRC-101 functions through Driver Antigen Engagement, a novel mechanism of action in oncology. This mechanism involves systemic delivery of an antibody that has been shown in preclinical models to engage the innate immune system, cause remodeling of the tumor microenvironment and drive T-cell mediated destruction of tumor cells. Atreca has identified the target of ATRC-101 as a ribonucleoprotein (RNP) complex. Underlining the rationale for human testing, ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical syngeneic tumor models, including one model in which PD-1 checkpoint inhibitors typically display limited activity. Further, ATRC-101 has been shown to react in vitro with a majority of human ovarian, non-small cell lung, colorectal, breast cancer and acral melanoma samples from multiple patients.

    About Atreca, Inc.
    Atreca is a biopharmaceutical company developing novel antibody-based cancer immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumor. These antibodies provide the basis for first-in-class therapeutic candidates, such as ATRC-101, with the potential to address unmet need in large groups of cancer patients. The company expects to commence a Phase 1b study evaluating ATRC-101, its lead product candidate, in multiple solid tumor cancers in early 2020. For more information on Atreca, please visit www.atreca.com

    Forward-Looking Statements
    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will", "expect," "believe," "potential," "continue," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our prospectus, dated June 19, 2019, as filed with the Securities and Exchange Commission (SEC) pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, which are available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts
    Atreca, Inc.
    Herb Cross
    Chief Financial Officer
    info@atreca.com

    Investors:
    Alex Gray, 650-779-9251, ext. 251
    agray@atreca.com

    Media:
    Sheryl Seapy, 213-262-9390
    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  35. REDWOOD CITY, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced that it will present at two upcoming investor conferences:

    • Stifel Healthcare Conference 2019
      Date: Tuesday, November 19, 2019
      Presentation Time: 10:55 a.m. EST
      Location: New York, NY

    • Evercore ISI HealthCONx Conference
      Date: Tuesday, December 3, 2019
      Presentation Time: 10:15 a.m. EST
      Location: Boston, MA

    Live audio webcasts of the presentations can be accessed through the Events & Presentations section of the company's website at ir.atreca.com. Archived replays of the webcasts will be available on the company's website…

    REDWOOD CITY, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced that it will present at two upcoming investor conferences:

    • Stifel Healthcare Conference 2019
      Date: Tuesday, November 19, 2019
      Presentation Time: 10:55 a.m. EST
      Location: New York, NY

    • Evercore ISI HealthCONx Conference
      Date: Tuesday, December 3, 2019
      Presentation Time: 10:15 a.m. EST
      Location: Boston, MA

    Live audio webcasts of the presentations can be accessed through the Events & Presentations section of the company's website at ir.atreca.com. Archived replays of the webcasts will be available on the company's website for 90 days following each live presentation.

    About Atreca, Inc.
    Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Atreca's discovery platform relies on the human immune system to discover unique antibody-target pairs from patients experiencing an active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets and provide the basis for novel clinical therapeutic candidates such as ATRC-101, the company's lead clinical candidate. The company expects to file an Investigational New Drug application for ATRC-101 by the end of 2019 and to commence a Phase 1b study in multiple solid tumor types in early 2020. For more information on Atreca, please visit www.atreca.com.

    Contacts
    Atreca, Inc.
    Herb Cross
    Chief Financial Officer
    info@atreca.com

    Investors:
    Alex Gray, 650-779-9251, ext. 251
    agray@atreca.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  36. REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced financial results for the third quarter ended September 30, 2019, and provided an overview of recent developments.

    "We continued to make strong progress this quarter with our Investigational New Drug (IND) application for our lead product candidate, ATRC-101 and expect to initiate a Phase 1b clinical trial in patients with solid tumors early next year," said John Orwin, Chief Executive Officer. "To highlight our progress we recently presented a poster at the annual SITC meeting describing the discovery and preclinical…

    REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced financial results for the third quarter ended September 30, 2019, and provided an overview of recent developments.

    "We continued to make strong progress this quarter with our Investigational New Drug (IND) application for our lead product candidate, ATRC-101 and expect to initiate a Phase 1b clinical trial in patients with solid tumors early next year," said John Orwin, Chief Executive Officer. "To highlight our progress we recently presented a poster at the annual SITC meeting describing the discovery and preclinical evaluation of ATRC-101, underscoring both our ability to leverage the human immune response to find novel antibody-target pairs, as well as the potential of ATRC-101 to become an important treatment option for patients with a variety of solid tumor cancers."

    Recent Developments and Highlights

    • Atreca presented a poster describing the preclinical evaluation of ATRC-101 at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019). The poster included preclinical data highlighting ATRC-101's robust and persistent anti-tumor activity as both monotherapy and in combination with PD-1 checkpoint inhibitors.
       
    • In August 2019, Atreca appointed Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, to the company's Board of Directors, who brings more than 20 years of drug development experience to the company.
    • In August 2019, the period for centralized opposition of patent rights at the European Patent Office (EPO) ended with respect to European Patent EP2702146B1, entitled "Identification of Polynucleotides Associated with a Sample", which was granted by the EPO in November 2018.  This patent is part of the portfolio of patents and patent applications exclusively licensed by the Board of Trustees of the Leland Stanford Junior University to Atreca that relates to Atreca's proprietary Immune Repertoire Capture® technology.

    Upcoming Milestones

    • Atreca anticipates completion of the IND process with the U.S. Food and Drug Administration for ATRC-101 by late 2019 and expects to initiate a Phase 1b clinical trial in patients with solid tumors in early 2020.

    Third Quarter 2019 Financial Results

    • As of September 30, 2019, cash and cash equivalents and short-term investments totaled $201.0 million.
       
    • Research and development expenses for the three months ended September 30, 2019 were $12.8 million, including non-cash share-based compensation expense of $920,000.
       
    • General and administrative expenses for the three months ended September 30, 2019 were $4.9 million, including non-cash share-based compensation expense of $958,000.
       
    • Atreca reported a net loss of $15.9 million, or basic and diluted net loss per share attributable to common stockholders of $0.57, for the three months ended September 30, 2019.

    About Atreca, Inc.
    Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Atreca's discovery platform relies on the human immune system to discover unique antibody-target pairs from patients experiencing an active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets and provide the basis for novel clinical therapeutic candidates such as ATRC-101, the company's lead clinical candidate. The company anticipates completion of the Investigational New Drug process for ATRC-101 by late 2019 and expects to commence a Phase 1b study in multiple solid tumor types with ATRC-101 in early 2020. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements
    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will", "expect," "believe," "potential," "continue," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our prospectus, dated June 19, 2019, as filed with the Securities and Exchange Commission (SEC) pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, which are available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.


    Atreca, Inc.
    Condensed Consolidated Balance Sheets
    (in thousands, except share and per share data)

        September 30,    December 31,   
        2019     2018    
        (Unaudited)        
    ASSETS              


    Current Assets
                 
    Cash and cash equivalents   $ 166,144     $ 114,504    
    Investments     34,894          
    Prepaid expenses and other current assets     5,434       2,721    
    Total current assets     206,472       117,225    
    Property and equipment, net     4,740       4,143    
    Deposits and other     1,506       316    
    Total assets   $ 212,718     $ 121,684    


    LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
                 


    Current Liabilities
                 
    Accounts payable   $ 2,757     $ 1,307    
    Accrued expenses     4,519       3,008    
    Other current liabilities     264       247    
    Total current liabilities     7,540       4,562    
    Capital lease obligations, net of current portion     65       100    
    Deferred rent     118       6    
    Preferred stock warrant liability           380    
    Total liabilities     7,723       5,048    
                   
    Convertible preferred stock           209,669    


    Stockholders' equity (deficit)
                 
    Common stock     3          
    Additional paid-in capital     348,942       3,593    
    Accumulated other comprehensive loss     43       (4 )  
    Accumulated deficit     (146,993 )     (96,622 )  
    Total stockholders' equity (deficit)     204,995       (93,032 )  
    Total liabilities and stockholders' equity (deficit)   $ 212,718     $ 121,684    



    Atreca, Inc.
    Condensed Consolidated Statements of Operations
    (in thousands, except share and per share data)
    (unaudited)

        Three Months Ended September 30,    Nine Months Ended
    September 30, 
        2019     2018     2019     2018  
                             
    Expenses                        
    Research and development   $ 12,812     $ 7,820     $ 40,447     $ 21,882  
    General and administrative     4,864       1,875       10,919       4,807  
    Total expenses     17,676       9,695       51,366       26,689  
    Interest and other income (expense)                        
    Other income     619       100       1,805       660  
    Interest income     1,189       23       2,328       112  
    Interest expense     (1 )     (3 )     (5 )     (7 )
    Preferred stock warrant liability revaluation           (57 )     (123 )     (30 )
    Foreign exchange loss     (1 )           (1 )      
    Loss on disposal of property and equipment                 (7 )     (1 )
    Loss before income tax expense     (15,870 )     (9,632 )     (47,369 )     (25,955 )
    Income tax expense     (1 )           (2 )     (1 )
    Net loss   $ (15,871 )   $ (9,632 )   $ (47,371 )   $ (25,956 )
    Net loss per share, basic and diluted   $ (0.57 )   $ (4.56 )   $ (4.03 )   $ (12.35 )
    Weighted-average shares used in computing net loss per share, basic and diluted     27,949,682       2,112,180       11,747,825       2,101,030  

    Contacts
    Atreca, Inc.
    Herb Cross
    Chief Financial Officer
    info@atreca.com

    Investors:
    Alex Gray, 650-779-9251, ext. 251
    agray@atreca.com

    Media:
    Sheryl Seapy, 213-262-9390
    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  37. REDWOOD CITY, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced that it will present a poster describing preclinical evaluations of ATRC-101 at the upcoming 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019), to be held from November 6-10 in National Harbor, MD. ATRC-101 is a novel, first-in-class therapeutic candidate that targets a tumor-associated ribonucleoprotein complex, derived from a human antibody discovered by Atreca's proprietary Immune Repertoire Capture® (IRC™) platform.

    The poster will describe the characterization and target of ATRC-101…

    REDWOOD CITY, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced that it will present a poster describing preclinical evaluations of ATRC-101 at the upcoming 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019), to be held from November 6-10 in National Harbor, MD. ATRC-101 is a novel, first-in-class therapeutic candidate that targets a tumor-associated ribonucleoprotein complex, derived from a human antibody discovered by Atreca's proprietary Immune Repertoire Capture® (IRC™) platform.

    The poster will describe the characterization and target of ATRC-101 and will include preclinical data highlighting ATRC-101's robust anti-tumor activity as monotherapy and favorable safety profile. Atreca remains on track to file an Investigational New Drug (IND) application for ATRC-101 during the fourth quarter of 2019, with plans to commence a Phase 1b study in multiple solid tumor types in early 2020.

    Details of the presentation are as follows:

    Presentation Title: "ATRC-101: A First-in-Class Engineered Fully Human Monoclonal Antibody that Targets a Tumor-Restricted Ribonucleoprotein Complex"
    Date: Saturday, November 9, 2019
    Time: 7:00AM – 8:30 PM PST
    Location: Gaylord National Hotel & Convention Center, National Harbor, MD
    Category: Novel Single-Agent Immunotherapies
    Poster/Abstract Number: P778
    Authors: Norman M. Greenberg, PhD, et al.

    About ATRC-101
    ATRC-101 is a monoclonal antibody derived from an antibody identified using Atreca's discovery platform. ATRC-101 functions through a novel mechanism of action, referred to by Atreca as Driver Antigen Engagement. This mechanism involves systemic delivery of an agent that causes extensive remodeling of the tumor microenvironment and the destruction of tumor cells via both the innate and adaptive immune systems. Atreca has identified the target of ATRC-101 as a ribonucleoprotein (RNP) complex. ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical syngeneic tumor models, including one model in which PD-1 checkpoint inhibitors typically display limited activity. ATRC-101 has also demonstrated preclinical activity in combination with other immunotherapeutics (including PD-1 checkpoint inhibitors). Further, ATRC-101 has been shown to react in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients.

    About Atreca, Inc.
    Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Atreca's discovery platform relies on the human immune system to discover unique antibody-target pairs from patients experiencing an active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets and provide the basis for novel clinical therapeutic candidates such as ATRC-101, the company's lead clinical candidate. The company expects to file an Investigational New Drug application for ATRC-101 in the fourth quarter of 2019 and to commence a Phase 1b study in multiple solid tumor types in early 2020. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements
    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will", "expect," "believe," "potential," "continue," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug application and other regulatory submissions, and other matters that are described in our prospectus, dated June 19, 2019, as filed with the Securities and Exchange Commission (SEC) pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, which are available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Contacts
    Atreca, Inc.
    Herb Cross
    Chief Financial Officer
    info@atreca.com

    Investors:
    Alex Gray, 650-779-9251, ext. 251
    agray@atreca.com

    Media:
    Sheryl Seapy, 213-262-9390
    sseapy@w2ogroup.com

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article